

## Lyme disease: diagnosis and management

[F] Evidence review for the management of  
neuroborreliosis

*NICE guideline 95*

*Evidence review*

*April 2018*

*Final*

*This evidence review was developed by  
the National Guideline Centre*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2018. All rights reserved. Subject to Notice of rights.

ISBN: 978-1-4731-2919-1

# Contents

<b>1</b>	<b>Management (Neuroborreliosis)</b> .....	<b>6</b>
1.1	Review question: What is the most clinically and cost-effective treatment for people with symptoms consistent with neuroborreliosis? .....	6
1.2	Introduction .....	6
1.3	PICO table .....	6
1.4	Clinical evidence .....	7
1.4.1	Included studies .....	7
1.4.2	Excluded studies .....	8
1.4.3	Summary of clinical studies included in the evidence review .....	8
1.4.4	Quality assessment of clinical studies included in the evidence review .....	11
1.5	Economic evidence .....	15
1.5.1	Included studies .....	15
1.5.2	Excluded studies .....	15
1.5.3	Unit costs .....	16
1.6	Resource impact .....	19
1.7	Evidence statements .....	19
1.7.1	Clinical evidence statements .....	19
1.7.2	Health economic evidence statements .....	19
1.8	The committee's discussion of the evidence .....	19
1.8.1	Interpreting the evidence .....	19
1.8.2	Cost effectiveness and resource use .....	21
1.8.3	Other factors the committee took into account .....	22
	<b>References</b> .....	<b>25</b>
	<b>Appendices</b> .....	<b>38</b>
	Appendix A: Review protocols.....	38
	Appendix B: Literature search strategies .....	43
	B.1 Clinical search literature search strategy .....	43
	B.2 Health Economics literature search strategy .....	45
	Appendix C: Clinical evidence selection .....	50
	Appendix D: Clinical evidence tables .....	51
	Appendix E: Forest plots .....	60
	E.1.1 Neuroborreliosis (unspecified) .....	60
	E.2 Doxycycline (PO) versus Ceftriaxone (IV) .....	61
	E.2.1 Neuroborreliosis (unspecified) .....	61
	E.3 Cefotaxime (IV) versus Benzylpenicillin (IV) .....	62
	E.3.1 Acute radiculitis or meningitis after tick-bite .....	62
	E.4 Cefotaxime (IV) versus Ceftriaxone (IV) .....	62
	E.4.1 Neuroborreliosis (unspecified) .....	62

E.5 Antibiotics versus Antibiotics plus Corticosteroids .....	62
E.5.1 Facial palsy .....	62
Appendix F: GRADE tables.....	64
Appendix G: Health economic evidence selection.....	69
Appendix H: Health economic evidence tables .....	70
Appendix I: Excluded studies .....	71
I.1 Excluded clinical studies .....	71
I.2 Excluded health economic studies.....	75

# 1 Management (Neuroborreliosis)

## 1.1 Review question: What is the most clinically and cost-effective treatment for people with symptoms consistent with neuroborreliosis?

## 1.2 Introduction

Lyme neuroborreliosis refers to Lyme disease infection of the nervous system, which includes the nerves, spinal cord and brain. There are a wide range of possible neurological presentations including facial nerve palsy (weakness), meningitis and painful sensory and motor radiculopathy (inflammation of a nerve root).

Neuroborreliosis can lead to significant ongoing symptoms. Prompt, effective treatment is therefore important. Current practice is informed by the site of infection with a number of different treatment regimens ranging from a 14–21 day course of oral doxycycline for facial nerve palsy to 14–28 days of intravenous ceftriaxone for more complex disease. This evidence report includes the evidence reviewed to make recommendations in this area and the committee discussions.

## 1.3 PICO table

For full details, see the review protocol in appendix A.

**Table 1: PICO characteristics of review question**

<b>Population</b>	Adults (18 years and over), young people (12 to 17 years) and children (under 12 years) with clinical presentations consistent with neuroborreliosis, such as: <ul style="list-style-type: none"> <li>• peripheral nervous system                             <ul style="list-style-type: none"> <li>○ radiculopathy</li> <li>○ mononeuritis multiplex</li> <li>○ peripheral neuropathy or polyneuropathy</li> <li>○ myopathy (for example, myositis)</li> <li>○ cranial nerve lesions including facial nerve (VII) palsy</li> <li>○ autonomic nerve dysfunction</li> </ul> </li> <li>• central nervous system                             <ul style="list-style-type: none"> <li>○ white matter lesions</li> <li>○ meningitis</li> <li>○ encephalitis</li> <li>○ seizures</li> <li>○ optic neuritis</li> <li>○ transverse myelitis</li> <li>○ movement disorders (for example, chorea, ataxia)</li> </ul> </li> <li>• psychiatric                             <ul style="list-style-type: none"> <li>○ psychosis</li> <li>○ depression</li> <li>○ cognitive decline including dementia</li> </ul> </li> </ul>
<b>Interventions</b>	Antimicrobials, including but not limited to: <ul style="list-style-type: none"> <li>• Penicillins                             <ul style="list-style-type: none"> <li>○ Amoxicillin (oral, IV)</li> <li>○ Ampicillin (oral, IV)</li> <li>○ Benzylpenicillin sodium / Penicillin G (IV)</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>- Including Augmentin (Amoxicillin and clavulanic acid; oral, IV)</li> <li>o Phenoxyethylpenicillin / Penicillin V (oral)</li> <li>• Tetracyclines <ul style="list-style-type: none"> <li>o Doxycycline (oral)</li> <li>o Minocycline (oral)</li> </ul> </li> <li>• Cephalosporins <ul style="list-style-type: none"> <li>o Cefotaxime (IV)</li> <li>o Ceftriaxone (IV)</li> <li>o Cefuroxime axetil (oral)</li> </ul> </li> <li>• Macrolides <ul style="list-style-type: none"> <li>o Azithromycin (oral)</li> <li>o Clarithromycin (oral, IV)</li> </ul> </li> <li>• Fluoroquinolones <ul style="list-style-type: none"> <li>o Ciprofloxacin (oral, IV)</li> <li>o Levofloxacin (oral, IV)</li> <li>o Moxifloxacin (oral, IV)</li> <li>o Nalidixic acid (oral)</li> <li>o Norfloxacin (oral)</li> <li>o Ofloxacin (oral, IV)</li> </ul> </li> <li>• Rifampicin (oral, IV)</li> </ul> <p>Steroids (corticosteroids)</p>
<b>Comparisons</b>	<ul style="list-style-type: none"> <li>• Any type of intervention compared to each other <ul style="list-style-type: none"> <li>o If data are available consider: <ul style="list-style-type: none"> <li>- Type of agent (within class or between class)</li> <li>- Route of administration</li> <li>- Duration of treatment: 1 month versus longer</li> </ul> </li> </ul> </li> <li>• Monotherapy versus polytherapy (any combination)</li> <li>• Antimicrobial treatment or steroids compared to no treatment / placebo</li> </ul>
<b>Outcomes</b>	<p><b>Critical:</b></p> <ol style="list-style-type: none"> <li>1. Quality of life (any validated measure)</li> <li>2. Cure (resolution of neuroborreliosis)</li> <li>3. Reduction of clinical symptoms related to neuroborreliosis</li> <li>4. Relapse of neuroborreliosis symptoms</li> </ol> <p><b>Important:</b></p> <ol style="list-style-type: none"> <li>5. Adverse events</li> </ol>
<b>Study design</b>	<ul style="list-style-type: none"> <li>• RCTs</li> <li>• Cohort studies (if no RCT evidence is found)</li> </ul>

## 1.4 Clinical evidence

### 1.4.1 Included studies

Six studies (7 papers) were included in the review;<sup>73,76,82,95,96,135,136</sup> these are summarised in Table 2 below. Evidence from these studies is summarised in the clinical evidence summary below (Table 3).

See also the study selection flow chart in appendix C, study evidence tables in appendix D, forest plots in appendix E and GRADE tables in appendix F.

A search was conducted for randomised controlled trials (RCTs) comparing the effectiveness of antibiotics versus each other or placebo as treatment for people with symptoms consistent

with neuroborreliosis. In the absence of sufficient evidence from RCTs, a search was conducted for observational studies.

Five RCTs were included in the review. All 5 RCTs were in adults. One retrospective cohort study comparing antibiotics with antibiotics plus corticosteroids was included in the review.<sup>73</sup> This study had an indirect population as it included children and adults.

One cohort study was in people with facial palsy,<sup>73</sup> 4 RCTs were in people with symptoms associated with neuroborreliosis<sup>76,82,94,136</sup> and 1 RCT was in people with acute radiculitis or meningitis with a history of a tick bite.<sup>135</sup>

#### 1.4.2 Excluded studies

See the excluded studies list in appendix I.

#### 1.4.3 Summary of clinical studies included in the evidence review

**Table 2: Summary of studies included in the evidence review**

Study	Intervention and comparison	Population	Outcomes	Comments
Jowett 2016 <sup>73</sup>	Antibiotics alone (n=18) duration not reported  Antibiotics plus Corticosteroids (n=17) duration not reported	n=51 (other treatment arm included antivirals, n=16)  Diagnosis: Lyme disease-associated facial palsy meeting CDC definition for confirmed Lyme disease (facial palsy in addition to EM with known tick exposure, or facial palsy in addition to laboratory evidence of infection consisting of a positive CSF antibody test or positive 2-tier serology testing)	Reduction of clinical symptoms (eFACE composite score)	Retrospective cohort study.  Indirect population - included children and adults.
Karlsson 1994 <sup>76</sup>	Doxycycline 200 mg orally every 24 hours for 14 days (n=38)  Benzylpenicillin sodium 3 g intravenously every 6 hours for 14 days (n=32)	n=70  Diagnosis: Clinical signs and symptoms compatible with Lyme neuroborreliosis and pleocytosis	Cure (resolution of symptoms)  Adverse events	RCT
Kohlhepp 1989 <sup>82</sup>	Doxycycline 200 mg orally on the first 2 days, 100 mg	n=75	Reduction of clinical symptoms	RCT

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>orally on each of the following 8 days (n=39)</p> <p>Benzylopenicillin sodium 20 mega units/day intravenously for 10 days (n=36)</p>	<p>Diagnosis: Elevated antibody titre specific to <i>B. burgdorferi</i> in the serum plus at least 3 of the following: radiculitis pain, meningitis symptoms, cranial neuritis, sensory or motor radiculitis, arthritis or carditis, tick bite or EM, specific antibody titre (serum or CSF), lymphocytic pleocytosis, elevated protein (&gt;50mg/dl), elevated IgM/IgG/IgA index</p>		<p>Indirect outcome – full or partial remission (unclear how many people had full remission and how many had partial remission)</p> <p>7 people had received previous antibiotics and 5 had received previous corticosteroids</p> <p>20 received ancillary treatment with corticosteroids</p>
<p>Ljostad 2008<sup>96</sup> Ljostad 2010<sup>95</sup></p>	<p>Doxycycline 200 mg orally per day for 14 days (n=59)</p> <p>Ceftriaxone 2 g intravenously per day for 14 days (n=59)</p>	<p>n=118</p> <p>Diagnosis: Neurological symptoms suggestive of Lyme neuroborreliosis plus 1 or more of the following: CSF white-cell count of &gt;5/mL, intrathecal production of Bb antibodies, verified acrodermatitis chronica atrophicans</p>	<p>Cure (resolution of symptoms)</p> <p>Reduction of clinical symptoms</p> <p>Adverse events</p>	RCT
Pfister 1989 <sup>135</sup>	<p>Cefotaxime 2 g 3 times per day intravenously for 10 days (n=11)</p> <p>Benzylopenicillin sodium 5 million U 4 times per day intravenously for 10 days (n=10)</p>	<p>n=21</p> <p>Diagnosis: Clinical signs of acute neuroborreliosis radiculitis (Bannwarth's syndrome) with severe radicular pain and lymphocytic pleocytosis in the CSF, elevated antibody titres against <i>B.</i></p>	Cure (resolution of symptoms)	RCT

Study	Intervention and comparison	Population	Outcomes	Comments
		<i>burgdorferi</i> or history of arthropod bite or erythema migrans; neuroborreliosis meningitis with history of tick bite or erythema migrans and elevated titres against <i>B. burgdorferi</i>		
Pfister 1991 <sup>136</sup>	Cefotaxime 2 g every 8 hours intravenously for 10 days (n=16)  Ceftriaxone 2 g every 24 hours intravenously for 10 days (n=17)	n=33  Diagnosis: Lyme neuroborreliosis (28 had typical Bannwarth's syndrome with intense radicular pain and lymphocytic pleocytosis in the CSF)	Cure (resolution of symptoms)  Reduction of clinical symptoms  Adverse events	RCT  Indirect outcome – mild residual symptoms – unclear whether symptoms were reduced from baseline

See appendix D for full evidence tables.

### 1.4.4 Quality assessment of clinical studies included in the evidence review

**Table 3: Clinical evidence summary: Doxycycline (PO) versus Benzylpenicillin (IV)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with benzylpenicillin	Risk difference with doxycycline (95% CI)
Cure (resolution of symptoms at 4 weeks) no residual symptoms	54 (1 study) 4 weeks	VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.89 (0.47 to 1.69)	435 per 1,000	48 fewer per 1,000 (from 230 fewer to 300 more)
Cure (resolution of symptoms at 3 months) no residual symptoms	53 (1 study) 3 months	VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.98 (0.62 to 1.55)	591 per 1,000	12 fewer per 1,000 (from 225 fewer to 325 more)
Cure (resolution of symptoms at 6 months) no residual symptoms	52 (1 study) 6 months	VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1 (0.76 to 1.3)	810 per 1,000	0 fewer per 1,000 (from 194 fewer to 243 more)
Cure (resolution of symptoms at 12 months) no residual symptoms	51 (1 study) 12 months	VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.05 (0.85 to 1.3)	857 per 1,000	43 more per 1,000 (from 129 fewer to 257 more)
Adverse events at 2 weeks adverse events	70 (1 study) 2 weeks	VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.12 (0.27 to 4.65)	94 per 1,000	11 more per 1,000 (from 68 fewer to 342 more)
Reduction of clinical symptoms (full/partial remission at 2 weeks) full or partial remission	75 (1 study) 2 weeks	VERY LOW <sup>1,2,3</sup> due to risk of bias, indirectness, imprecision	RR 1.05 (0.85 to 1.29)	806 per 1,000	40 more per 1,000 (from 121 fewer to 234 more)

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias  
<sup>2</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs  
<sup>3</sup> Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes

**Table 4: Clinical evidence summary: Doxycycline (PO) versus Ceftriaxone (IV)**

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with ceftriaxone	Risk difference with doxycycline (95% CI)
Cure (clinical score=0 at 4 months) clinical score=0	102 (1 study) 4 months	LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.44 (0.89 to 2.35)	333 per 1,000	147 more per 1,000 (from 37 fewer to 450 more)
Cure (complete recovery at 1 year) complete recovery	85 (1 study) 1 years	LOW <sup>2</sup> due to imprecision	RR 0.93 (0.62 to 1.4)	537 per 1,000	38 fewer per 1,000 (from 204 fewer to 215 more)
Reduction of clinical symptoms at 13 days improvement in clinical score; 0-64, lower values are beneficial	102 (1 study) 13 days	LOW <sup>1,2</sup> due to risk of bias, imprecision	Not applicable	The mean reduction of clinical symptoms at 13 days in the control group was 3.6 (SD 3.4)	The mean reduction of clinical symptoms at 13 days in the intervention group was 0.6 lower (1.98 lower to 0.78 higher)
Reduction of clinical symptoms at 4 months improvement in clinical score; 0-64, lower values are beneficial	102 (1 study) 4 months	MODERATE <sup>1</sup> due to risk of bias	Not applicable	The mean reduction of clinical symptoms at 4 months in the control group was 4.4 (SD 3.44)	The mean reduction of clinical symptoms at 4 months in the intervention group was 0.1 higher (1.21 lower to 1.41 higher)
Adverse events any adverse events	113 (1 study)	LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.79 (0.51 to 1.23)	464 per 1,000	97 fewer per 1,000 (from 227 fewer to 107 more)
Adverse events serious adverse events	113 (1 study)	VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	OR 0.13 (0.01 to 1.26) <sup>3</sup>	54 per 1,000	46 fewer per 1,000 (from 53 fewer to 13 more)
<p><sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p><sup>2</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs</p> <p><sup>3</sup> The Peto odds ratio method was used because of a zero event rate in the intervention arm</p>					

**Table 5: Clinical evidence summary: Cefotaxime (IV) versus Benzylpenicillin (IV)**

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with benzylpenicillin	Risk difference with cefotaxime (95% CI)
Cure (normal neurologic findings at mean 7.7 months) normal neurologic findings	21 (1 study) 7.7 months	VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 1.02 (0.67 to 1.55)	800 per 1,000	16 more per 1,000 (from 264 fewer to 440 more)
<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias <sup>2</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs					

**Table 6: Clinical evidence summary: Cefotaxime (IV) versus Ceftriaxone (IV)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with ceftriaxone	Risk difference with cefotaxime (95% CI)
Cure (normal neurologic findings at mean 8.1 months) normal neurologic findings	27 (1 study) 8.1 months	VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 0.9 (0.51 to 1.6)	667 per 1,000	67 fewer per 1,000 (from 327 fewer to 400 more)
Reduction of symptoms (mild residual symptoms at mean 8.1 months) mild residual symptoms	27 (1 study) 8.1 months	VERY LOW <sup>1,2,3</sup> due to risk of bias, indirectness, imprecision	RR 1.33 (0.4 to 4.49)	250 per 1,000	83 more per 1,000 (from 150 fewer to 872 more)
Adverse events during treatment adverse reactions	30 (1 study)	VERY LOW <sup>1,2</sup> due to risk of bias, imprecision	RR 2.62 (0.31 to 22.46)	71 per 1,000	116 more per 1,000 (from 49 fewer to 1,000 more)
<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias <sup>2</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs <sup>3</sup> Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes					

**Table 7: Clinical evidence summary: Antibiotics versus Antibiotics plus Corticosteroids**

Outcomes	No of	Quality of the evidence	Relative	Anticipated absolute effects
----------	-------	-------------------------	----------	------------------------------

	Participants (studies) Follow up	(GRADE)	effect (95% CI)	Risk with antibiotics plus steroids	Risk difference with antibiotics (95% CI)
Reduction of symptoms (eFACE composite score at 3 months) eFACE composite score; 0-100, higher values are beneficial	35 (1 study) <sup>1</sup> 3 months	VERY LOW <sup>2,3,4</sup> due to risk of bias, indirectness, imprecision	Not applicable	Not applicable	The mean reduction of symptoms (eFace composite score at 3 months) in the intervention groups was 9.62 higher (0.19 to 19.05 higher)
Reduction of symptoms (eFACE composite score at 6 months) eFACE composite score; 0-100, higher values are beneficial	35 (1 study) <sup>1</sup> 6 months	VERY LOW <sup>2,3,4</sup> due to risk of bias, indirectness, imprecision	Not applicable	Not applicable	The mean reduction of symptoms (eFace composite score at 6 months) in the intervention groups was 11.4 higher (1.61 to 21.19 higher)
Reduction of symptoms (eFACE composite score at 12 months) eFACE composite score; 0-100, higher values are beneficial	35 (1 study) <sup>1</sup> 12 months	VERY LOW <sup>2,3,4</sup> due to risk of bias, indirectness, imprecision	Not applicable	Not applicable	The mean reduction of symptoms (eFace composite score at 12 months) in the intervention groups was 13.7 higher (2.16 lower to 29.56 higher)
<sup>1</sup> Observational study <sup>2</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias <sup>3</sup> Downgraded by 1 or 2 increments because the majority of the evidence included an indirect population (downgrade by 1 increment) or a very indirect population (downgrade by 2 increments) <sup>4</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs					

See appendix F for full GRADE tables.

## **1.5 Economic evidence**

### **1.5.1 Included studies**

No relevant health economic studies were identified.

See also the health economic study selection flow chart in appendix G.

### **1.5.2 Excluded studies**

One economic study relating to this review question was identified but was excluded due to limited applicability.<sup>127</sup> This is listed in appendix I, with reasons for exclusion given.

### 1.5.3 Unit costs

The following unit costs were presented to the committee to aid consideration of cost-effectiveness.

**Table 8: UK costs of antimicrobials**

Class	Drug	Age	Preparation	Mg/unit	Cost/unit (£)	Units/day	Course duration (days)	Cost per course (£)
Penicillins	Amoxicillin	7 days-11 months	125 mg/1.25ml oral suspension paediatric	125	0.20	3	14–28	8.35–16.70
		1-4 years	250 mg/5ml oral suspension	250	0.06	3	14–28	2.37–4.75
		>5 years	capsules	500	0.06	3	14–28 (g)	2.54–5.08
Penicillins	Phenoxymethylpenicillin	Adults (a)	tablets	250	0.04	4	10	1.49
Tetracyclines	Doxycycline	>12 years	capsules	100	0.11	2	10–28 (h)	2.18–6.09
Cephalosporins	Cefuroxime axetil	>3 months	tablets	250	1.27	4	14–28 (g)	70.88–141.76
Macrolide	Clarithromycin	>1 month	tablets	500	0.16	2	14–21	4.42–6.63
Macrolide	Azithromycin	<12 years	40 mg/1ml oral suspension	40	0.27	10 mg/kg	9 (i)	Weight dependent
		Adults	tablets	500	0.42	1	9 (i)	3.75
Cephalosporins	Cefotaxime	Adults (b)	2 g powder for solution for injection vials (IV)	2000	3.75	3	10	112.50
Cephalosporins	Ceftriaxone	>9 years (c)(d)	2 g powder for solution for injection vials (IV) (e)	2000	1.03	1	14–21	14.42–21.63
Penicillins	Benzylpenicillin sodium	Adults (f)	600 mg powder for solution for injection vials (IM)	600	2.73	2	3	16.38

Abbreviations: IM: intramuscular; IV: intravenous.

Sources: Unit costs from NHS Electronic Drug Tariff January 2017,<sup>123</sup> except cefotaxime from BNF, January 2017<sup>20</sup> and ceftriaxone from EMIT March 2017;<sup>37</sup> dosage from BNF and BNF for Children January 2017,<sup>20,21</sup> exceptions below:

- (a) Source of dosage from RCT in adults with ECM: Steere 1983,<sup>170</sup> dosage for Lyme disease not available from BNF or BNF for children.
- (b) Source of dosage from RCT in adults with neuroborreliosis: Pfister 1989<sup>135</sup> and Pfister 1991,<sup>136</sup> dosage for Lyme disease not available from BNF or BNF for children.<sup>20,21</sup>
- (c) For disseminated Lyme borreliosis.
- (d) Dose for neonate and child up to 11 years (body weight <50 kg) 50-80 mg/kg once daily for 14-21 days. BNF for children January 2017.<sup>21</sup>
- (e) Administration can vary in adults and children >1 month: IV infusion over 30 mins or IV injection over 5 mins or deep muscular injection (doses over 1 g divided between more than 1 site): 2 g per day for 14-21 days BNF January 2017.<sup>20</sup>
- (f) Source of dosage from RCT in adults with Lyme arthritis: Steere 1985:<sup>169</sup> 1.2 million U injected in each buttock weekly intramuscularly. Duration 3 weeks. Dosage for Lyme disease not available from BNF or BNF for children.<sup>20,21</sup>
- (g) Course duration for early Lyme 14-21 days; 28 days for Lyme arthritis. BNF January 2017.<sup>20</sup>
- (h) Course duration for early Lyme 10-14 days; 28 days for Lyme arthritis. BNF January 2017.<sup>20</sup>
- (i) Course dose and duration for adults: 500 mg once daily for 3 days for 3 weeks. For children under 12 years, 10 mg/kg once daily for 3 days for 3 weeks. Committee expert opinion.

The cost of intravenous antibiotics will vary depending on where these are administered and by whom. These costs will include some of the following cost components:

- antibiotic
- nursing time (for example, Band 6 nurse, £44 per hour, PSSRU 2016<sup>40</sup>)
- clinic space and clerical time (for outpatient administration)
- travel time (for home administration)
- hospital bed (for inpatient administration)
- consumables (for example, cannula, needles, syringes, dressing, IV giving set and glucose or sodium chloride solution).

A large proportion of the total cost of intravenous antibiotics is likely to be the cost of administration rather than the drug itself. As a result, intravenous drugs that have multiple doses administered per day will be more costly than those administered once daily. This was explored in a detailed costing analysis conducted for the NICE CG102 (Meningitis [bacterial] and meningococcal septicaemia in under 16s).<sup>120</sup> In this analysis, they found that ceftriaxone was the cheapest antibiotic when compared to cefotaxime and benzylpenicillin. This was due to savings in staff time associated with once daily dosing, which offset the higher cost of the drug itself.

### Inpatient administration

Intravenous antibiotics administered in an inpatient setting will incur the cost of an inpatient stay, which is assumed to include intravenous antibiotics treatment as part of the unit cost. The weighted average unit cost of non-elective inpatient stays and day cases for infectious disease in adults and children are summarised estimated in the table below using the NHS reference costs 2015-2016.<sup>45</sup>

**Table 9: Unit costs of inpatient administration**

Schedule	Currency description	Currency codes	Weighted average unit costs (per day)
Day-case adults	Standard/major/complex infectious diseases with/without single/multiple interventions, with/without CC	WJ01B, WJ01D, WJ01E, WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F, WJ03G	£352
Day-case paediatrics	Paediatric minor/major/intermediate infections with/without CC	PW01A, PW01B, PW01C, PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E, PW17F, PW17G	£448
Non-elective inpatient short-stay adults	Standard/major/complex infectious diseases with/without single/multiple interventions, with/without CC	WJ01A, WJ01B, WJ01C, WJ01D, WJ01E, WJ02A, WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F, WJ03G	£432
Non-elective inpatient short-stay paediatrics	Paediatric minor/major/intermediate infections with/without CC	PW01A, PW01B, PW01C, PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E, PW17F, PW17G	£521
Non-elective inpatient long-stay adults	Standard/major/complex infectious diseases with/without single/multiple interventions, with/without CC	WJ01A, WJ01B, WJ01C, WJ01D, WJ01E, WJ02A, WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F, WJ03G	£473
Non-elective inpatient long-stay paediatrics	Paediatric minor/major/intermediate infections with/without CC	PW01A, PW01B, PW01C, PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E, PW17F, PW17G	£699

Source: NHS reference costs 2015/2016<sup>45</sup>

### Outpatient administration

Intravenous antibiotics may also be administered as part of an outpatient parenteral antibiotic therapy (OPAT) service, which is available in some hospitals. This allows for administration in an outpatient clinic or in a home setting by a district nurse and is for people who require parenteral treatment but are otherwise stable and well enough not to be in hospital. There is currently no NHS reference cost for this service.

A UK study by Chapman 2009<sup>29</sup> reports that this type of service costs between 41% and 61% of the equivalent inpatient costs. Based on these estimates from Chapman 2009 and the unit cost for an adult day case in Table 9, the cost of OPAT would be approximately £144 to £215 per day. These costs would include the cost of the drug as well as the administration.

## 1.6 Resource impact

We do not expect recommendations resulting from this review area to have a significant impact on resources.

## 1.7 Evidence statements

### 1.7.1 Clinical evidence statements

Adults and young people (aged 12 and over):

- Very Low quality evidence from 1 RCT showed there was no clinically important difference between oral doxycycline and intravenous benzylpenicillin.
- Low quality evidence from 1 RCT showed a higher cure rate at 4 months for oral doxycycline over intravenous ceftriaxone, but no difference in cure rates at 12 months between the treatment arms. Moderate to Low quality evidence from 1 RCT showed no clinical difference between oral doxycycline and intravenous ceftriaxone in terms of a reduction of symptoms. Low to Very Low quality evidence from 1 RCT also found no difference in adverse events.
- Very Low quality evidence from 1 RCT showed there was no clinically important difference between intravenous cefotaxime and intravenous benzylpenicillin.
- Very Low quality evidence from 1 RCT found that people taking intravenous cefotaxime were more likely to experience adverse events compared to people taking intravenous ceftriaxone. Very Low quality evidence from 1 RCT found no difference in cure rates or reduction of symptoms.
- Very Low quality evidence from 1 cohort study showed that in people with a facial palsy associated with Lyme disease antibiotics alone resulted in a greater reduction of symptoms compared to antibiotics plus steroids.

Children (under 12 years):

- No relevant evidence in children was identified.

### 1.7.2 Health economic evidence statements

No relevant economic evaluations were identified.

## 1.8 The committee's discussion of the evidence

### 1.8.1 Interpreting the evidence

#### 1.8.1.1 The outcomes that matter most

The guideline committee considered quality of life, cure or the resolution of neurological symptoms, reduction in neurological symptoms and the reoccurrence of neurological symptoms to be critical outcomes to decision-making. They also considered adverse events to be an important outcome.

This review did not identify any evidence for quality of life.

#### 1.8.1.2 The quality of the evidence

The evidence came from six studies with small sample sizes and was of Moderate to Very Low quality due to risk of bias, imprecision and indirectness. There were particular concerns

about a lack of blinding of study participants, healthcare professionals who administered the treatment, and outcome assessors. Blinding is of particular importance for subjective outcomes, which are reported by a person with the disease and that cannot be objectively measured. Many studies did not fully report on the method of randomisation that had been used. Pre-treatment durations and the cohort of people also varied in studies. Some of the people included had peripheral neuroborreliosis, while others had neuroborreliosis affecting the central nervous system.

Outcomes and the time point at which they were assessed were poorly defined in the included studies. In particular, it was not clear whether cure or reduction of symptoms referred to the resolution or improvement of the neurological symptoms or of any Lyme disease symptoms. Similar ambiguity existed for the outcomes of reoccurrence of symptoms. Studies also varied in the outcomes they reported. In some studies cure, defined as no residual symptoms after a given time, was the primary outcome. However, the committee agreed that the treatment of neuroborreliosis may eliminate the bacteria, but the person may continue to have residual neurological symptoms as neurological damage may take time to resolve and full recovery may not occur. The committee acknowledged that there is currently no test of cure.

### **1.8.1.3 Benefits and harms**

#### **1.8.1.3.1 *Treatment of neuroborreliosis affecting the peripheral nervous system (including the cranial nerves)***

The committee agreed to recommend 100 mg of oral doxycycline twice daily for 21 days. In cases where doxycycline is contraindicated, the committee recommended 1 g of oral amoxicillin 3 times per day for 21 days.

Only 1 study in people with facial palsy related to Lyme disease was identified. The study compared a combination of antibiotics and steroids with antibiotics alone but did not specify which antibiotics people had received. The evidence which was of very low quality showed that antibiotics alone were more effective in reducing symptoms than antibiotics with steroids combined. The committee were aware that steroids are recommended treatment for Bell's palsy. On the limited evidence available, the use of steroids when facial palsy is clearly caused by Lyme might not add additional benefit.

The committee used the evidence on the effectiveness of doxycycline in people with meningitis, radiculitis, pleocytosis and other signs and symptoms suggestive of neuroborreliosis to inform their decision as well as their clinical experience and current clinical practice.

Evidence from 1 study showed a clinical benefit of a 14-day treatment of oral doxycycline 200 mg over a 14-day treatment of intravenous ceftriaxone 2 g, although overall cure rates were low in both treatment arms. The committee also noted that the length of treatment in the study was below the maximum treatment durations recommended by some current guidelines.

Evidence from 1 small study found no difference between oral doxycycline (200 mg once on the first day followed by 100 mg once daily for 8 days) and intravenous benzylpenicillin (20 million units per day for 10 days) for any of the outcomes reported. There was also no difference between intravenous benzylpenicillin (5 million units 4 times per day for 10 days) and intravenous cefotaxime (2 g 3 times per day for 10 days) in another small study. The committee therefore decided not to recommend intravenous benzylpenicillin for neuroborreliosis affecting the peripheral nervous system.

#### **1.8.1.3.2 *Treatment of neuroborreliosis affecting the central nervous system***

The committee agreed to recommend 4 g of intravenous ceftriaxone daily for 21 days.

Although the evidence showed that there were less adverse events for ceftriaxone, the committee agreed that the evidence did not provide a clear benefit of cefotaxime over ceftriaxone, probably because of differences in dosages. The committee also agreed based on their clinical knowledge that there is no scientific basis for differences between the 2 drugs if equivalent dosages are used.

Ceftriaxone was also recommended over cefotaxime for practical and economic reasons. The committee acknowledged that cefotaxime was not as easily available as ceftriaxone, which can be administered via outpatient parenteral antibiotic therapy (OPAT) in the community nearer to the person's home on a once daily basis while cefotaxime requires a 3-times-per-day dosage. For people with CNS disease, the committee acknowledged the potentially serious negative outcome of inadequate levels of antibiotics. Intravenous treatment was considered to be helpful for ensuring that the treatment had been completed, as it is easier to monitor.

### 1.8.2 Cost effectiveness and resource use

No relevant health economic evidence was identified. The unit costs of different oral and intravenous antimicrobials were presented to the committee. The cost of oral doxycycline and amoxicillin is much lower than that of intravenous ceftriaxone (£4.57 and £7.62 versus £43.26 for adults). The committee also considered the cost of intravenous administration, which would include the cost of nurse time, clinic space and clerical time (if administered in an outpatient setting), nurse travel time (if administered at home) and disposables required for administration. These costs would likely be greater than the cost of the antibiotics themselves.

For presentations of neuroborreliosis affecting the cranial nerves or the peripheral nervous system, such as radiculopathy, the committee considered that oral doxycycline or amoxicillin (where doxycycline is contraindicated) should be offered, as none of the currently available clinical evidence indicates that intravenous antibiotics are more effective; therefore, the additional cost and risks associated with the administration of intravenous antibiotics are not justifiable. Although the evidence showed a clinical benefit of a 14-day treatment of oral doxycycline, the committee agreed to recommend a 21-day course based on their clinical experience and to reduce any ambiguity around treatment duration. This is discussed in greater detail below in the section entitled 'Other factors the committee took into account'. The committee recommended a higher dose of amoxicillin (1 g 3 times per day versus 500 mg 3 times per day in BNF). The rationale for this higher dose is based on the fact that evidence in other presentations of Lyme disease (for example, EM) used probenecid to increase the concentration of amoxicillin with improved outcome; therefore, the committee decided to recommend 1 g amoxicillin 3 times per day as the preferred dose of amoxicillin.

For presentations of neuroborreliosis affecting the central nervous system, the committee noted that people who present with meningitis (prior to a diagnosis of Lyme disease being confirmed) would be likely to receive ceftriaxone intravenously. Based on the clinical evidence and their expert opinion, the committee agreed that in some circumstances clinicians could switch people from intravenous to oral antibacterials if the person was clinically stable and when there is good bioavailability of the oral agent. This reduces the risk of line infection and allows people to be discharged thereby reducing costs of treatment to the NHS. However, there is no direct evidence for this in Lyme disease and it may increase the risk of non-adherence. Doxycycline would be the preferred antibiotic if such a switch was made.

Currently, the BNF recommends intravenous ceftriaxone for those with disseminated Lyme borreliosis at a dose of 2 g per day for 14–21 days for adults and children 9 to 18 years with body weight over 50 kg. For children 1 month to 12 years with a body weight below 50 kg, the BNF recommends a dose of 50–80 mg/kg once daily for 14–21 days to a maximum of 4 g daily. The higher dose of ceftriaxone was chosen for adults based on the evidence of a high

equivalent effective dose of cefotaxime. Also, the committee discussed the doses used in the management of neurosyphilis (see section below for further detail) and the committee considered that this upper dose of 4 g is also required for neuroborreliosis affecting the central nervous system).

Finally, ceftriaxone was chosen over cefotaxime due to the impracticality of 3 daily infusions required for cefotaxime versus once daily infusion for ceftriaxone. This would increase costs as demonstrated in a costing analysis conducted for the NICE CG102 (Meningitis [bacterial] and meningococcal septicaemia in under 16s) and may require an inpatient stay rather than a home administration by a district nurse.

The recommendations for children closely reflect those for adults, unless drugs are contraindicated. For younger children, oral suspension formulations may be required rather than tablets. The unit costs of the recommended antimicrobials for children are not dissimilar to those for adults.

The committee considered the different adverse event profiles of different antimicrobials and whether these may impact the costs of managing Lyme disease as well as their impact on the patient's quality of life. Doxycycline adverse events, for example, include photosensitivity, nausea and vomiting. In practice, if a person experiences any of these adverse events, these would be managed by switching to another antimicrobial; therefore, the cost to the NHS would be a consultation with a GP and additional antimicrobials. These costs are considered to be low and would be offset by the cure and reduction of symptoms after successful treatment of Lyme disease.

The committee agreed that this potential change in practice in terms of a longer course of antimicrobials for some individuals would not result in a significant resource impact given the number of people affected.

### **1.8.3 Other factors the committee took into account**

The committee agreed that neurological symptoms and conditions, such as nerve damage, take an extended period of time to improve or resolve. Minimising delay in treatment is therefore important and would hopefully minimise nerve damage and result in better outcomes. The committee discussed extensively the choice of antibiotic for various clinical presentations of neuroborreliosis, including clinical scenarios that could lead to a switch from 1 type of antibiotic to another.

The limited evidence did not show a clear superiority of intravenous antibiotics over oral antibiotics for neuroborreliosis. Central nervous system neurological infections have the potential to be catastrophic and result in permanent or long-term damage or disability, which influenced the committee's recommendation for intravenous treatment for people presenting with symptoms consistent with central nervous system infection.

People with a more severe CNS involvement, such as encephalitis, are likely to have already received an initial dose, or doses, of intravenous ceftriaxone treatment prior to a diagnosis of Lyme disease. The committee, however, agreed that a switch from intravenous ceftriaxone to oral doxycycline might be indicated for people with Lyme disease who are clinically stable, as doxycycline is known to have good central nervous system bioavailability (see below). People who develop an allergic reaction to intravenous ceftriaxone should also be given oral doxycycline instead. The committee agreed that a switch from intravenous to oral antibiotics is part of current clinical practice and frequently done for other infectious diseases; the same would apply to Lyme disease.

Non-compliance or intolerance with doxycycline may be a justification for switching to intravenous ceftriaxone

The committee was informed by an expert witness and by the BASHH (British Association for Sexual Health and HIV) guideline for syphilis. The management of neurosyphilis was considered relevant for the development of borreliosis affecting the central nervous system. BASHH guidelines recommend intramuscular procaine penicillin (1.8–2.4 million units once daily) plus 500 mg probenecid for 14 days or intravenous benzylpenicillin (10.8–14.4 g given as 1.8–2.4 g every 4 hours) for 14 days. Alternatively, oral doxycycline (200 mg twice daily for 28 days), oral amoxicillin (2 g 3 times daily for 28 days) plus probenecid (500 mg 4 times per day for 28 days) or intramuscular or intravenous ceftriaxone (2 g for 10–14 days) can be given. The evidence underpinning these recommendations was, however, limited and of very poor quality. There was only 1 small study from 1985 each for doxycycline, amoxicillin and procaine penicillin. The evidence informing the recommendations of intramuscular or intravenous ceftriaxone included case reports, people with an HIV co-infection and animal studies.

The SPC for ceftriaxone recommends up to 4g for bacterial meningitis with the higher end of recommended dose range suggested in documented bacteraemia. The committee considered that the potentially catastrophic effects of neuroborreliosis made it difficult to recommend more limited treatment despite the lack of good evidence. The committee acknowledged that they did not have evidence for the superiority of 4g ceftriaxone over 2g and that this is the dose many people previously treated for Lyme disease will have had.

The committee acknowledged the recommendations for Lyme disease developed by the European Federation of Neurological Societies (EFNS; now European Academy of Neurology, EAN). That guideline recommends 200 mg oral doxycycline per day or 2 g intravenous ceftriaxone per day for 14 days for symptoms confined to the meninges, cranial nerves, nerve roots or peripheral nerves. The guideline also recommends 2 g intravenous ceftriaxone per day for 14–21 days for CNS manifestations, such as myelitis, encephalitis or vasculitis. Treatment duration is dependent on the duration of symptoms, with a 3-week course of intravenous ceftriaxone being recommended for CNS manifestations for longer than 6 months. The committee acknowledged that the EFNS guideline was supported by very limited evidence and agreed to recommend a treatment duration of 21 days to reduce any ambiguity around treatment duration. The committee also agreed that oral doxycycline should be the treatment of choice for Lyme disease affecting the peripheral nervous system. Amoxicillin should be offered in cases where doxycycline is contraindicated.

The committee also discussed the penetration of oral doxycycline into the CSF. Research showed that CSF penetration 2–3 hours after 200 mg of oral doxycycline had been given was 15% with a concentration of 1.1 microgram per millilitre. With a doxycycline dose of 100 mg every 12 hours, the CSF concentration was only 0.6 microgram per millilitre 2–3 hours after administration.<sup>53</sup> The committee considered this provided additional justification for higher dose of doxycycline.

The guideline recommends that care of children and young people less than 18 years should be discussed with a specialist for advice about diagnosis and management. For children under the age of 12 amoxicillin is recommended as the antibiotic of choice. However the guideline committee was aware that specialists do offer doxycycline in children aged 9 years and above as a result of indirect evidence from the United States and Scandinavia despite no licence or BNFC dose. There is also increasing indirect evidence from use in other conditions in the United States and Canada that doxycycline does not cause teeth staining when used for short course (less than 4 weeks) in children aged 2 years and older and international practice is moving to recommend use above 2 years. UK specialist clinicians may choose to use doxycycline as second line where a CSF-penetrating oral antibiotic is required, although the lack of direct evidence, lack of licence and lack of BNFC dose regimen has so far limited UK use in children aged 8 and under. Where used, in the United States and Canada, 1 dose regimen of doxycycline for children under 45 kilograms is: 5 milligram/kilogram in 2 divided doses on day 1 followed by 2.5 milligram/kilogram daily in 1 or 2 divided doses with a maximum for severe infections, up to 5 milligram/kilogram daily.

Azithromycin should otherwise be offered in cases where amoxicillin is contraindicated.

The committee made a general research recommendation for development of core outcome set and for antibiotic management of Lyme disease. The details of these are in appendix J of evidence report D.

## References

1. Aberer E, Kahofer P, Binder B, Kinaciyan T, Schauerl H, Berghold A. Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin. *Dermatology*. 2006; 212(2):160-167
2. Abrutyn E. New uses for old drugs. *Infectious Disease Clinics of North America*. 1989; 3(3):653-664
3. Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of *Borrelia burgdorferi* to five oral cephalosporins and ceftriaxone. *Antimicrobial Agents and Chemotherapy*. 1992; 36(8):1788-1790
4. Agus B. The recognition and treatment of Lyme disease. *Primary Care Update for Ob/Gyns*. 1995; 2(6):200-203
5. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylicyclines. *Journal of Antimicrobial Chemotherapy*. 2006; 58(2):256-265
6. Ahmed A. When is facial paralysis Bell palsy? current diagnosis and treatment. *Cleveland Clinic Journal of Medicine*. 2005; 72(5):398-405
7. Ahmed S, Rashid S, Chaudhary A, Bischof E. A patient with Lyme disease: complete heart block treated with antibiotics. *Primary Care Cardiovascular Journal*. 2013; 6(3):117-118
8. Alarcon GS, Mikhail IS. Antimicrobials in the treatment of rheumatoid arthritis and other arthritides: a clinical perspective. *American Journal of the Medical Sciences*. 1994; 308(3):201-209
9. Andiman WA. Lyme disease: epidemiology, etiology, clinical spectrum, diagnosis, and treatment. *Advances in Pediatric Infectious Diseases*. 1986; 1:163-186
10. Anonymous. Antibiotic prophylaxis of Lyme disease following recognized tick bite. Bacterial Zoonoses Branch, Division of Vector-Borne Infectious Diseases National Center for Infectious Diseases, Centers for Disease Control. *Connecticut Medicine*. 1991; 55(12):691-693
11. Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. *Infectious Disease Clinics of North America*. 2015; 29(2):269-280
12. Auwaerter PG, Aucott J, Dumler JS. Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment. *Expert Reviews in Molecular Medicine*. 2004; 6(2):1-22
13. Bennet L, Danell S, Berglund J. Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin. *Scandinavian Journal of Infectious Diseases*. 2003; 35(2):129-131
14. Berende A, ter Hofstede HJ, Donders AR, van Middendorp H, Kessels RP, Adang EM et al. Persistent Lyme Empiric Antibiotic Study Europe (PLEASE)--design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis. *BMC Infectious Diseases*. 2014; 14:543
15. Berger BW. Treating erythema chronicum migrans of Lyme disease. *Journal of the American Academy of Dermatology*. 1986; 15(3):459-463

16. Berger BW. Treatment of erythema chronicum migrans of Lyme disease. *Annals of the New York Academy of Sciences*. 1988; 539:346-351
17. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete *Borrelia burgdorferi*. *Journal of Infectious Diseases*. 2009; 199(9):1379-1388
18. Bhate C, Schwartz RA. Lyme disease: Part II. Management and prevention. *Journal of the American Academy of Dermatology*. 2011; 64(4):639-653
19. Bjark PH. Re: No prolonged antibiotic therapy for disease attributed to borreliosis. *Tidsskrift for den Norske Laegeforening*. 2016; 136(20):1702-1703
20. BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National Formulary. Available from: <https://www.evidence.nhs.uk/formulary/bnf/current> Last accessed: 04 April 2017.
21. BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National Formulary for Children. Available from: <https://www.evidence.nhs.uk/formulary/bnf/current> Last accessed: 04 April 2017.
22. Borg R, Dotevall L, Hagberg L, Maraspin V, Lotric-Furlan S, Cimperman J et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. *Scandinavian Journal of Infectious Diseases*. 2005; 37(6-7):449-454
23. Bratton RL, Whiteside JW, Hovan MJ, Engle RL, Edwards FD. Diagnosis and treatment of lyme disease. *Mayo Clinic Proceedings*. 2008; 83(5):566-571
24. Bremell D, Dotevall L. Oral doxycycline for Lyme neuroborreliosis with symptoms of encephalitis, myelitis, vasculitis or intracranial hypertension. *European Journal of Neurology*. 2014; 21(9):1162-1167
25. British Infection Association. The epidemiology, prevention, investigation and treatment of Lyme borreliosis in United Kingdom patients: A position statement by the British Infection Association. *Journal of Infection*. 2011; 62(5):329-338
26. Butler T, Jones PK, Wallace CK. *Borrelia recurrentis* infection: single-dose antibiotic regimens and management of the Jarisch-Herxheimer reaction. *Journal of Infectious Diseases*. 1978; 137(5):573-577
27. Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Antibiotics for the neurological complications of Lyme disease. *Cochrane Database of Systematic Reviews* 2016, Issue 12. Art. No.: CD006978. DOI: 10.1002/14651858.CD006978.pub2.
28. Canadian Paediatric Society. How to diagnose and treat Lyme disease in children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. *CMAJ*. 1992; 147(2):169-178
29. Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. *Journal of Antimicrobial Chemotherapy*. 2009; 64(6):1316-1324
30. Chen J, Field JA, Glickstein L, Molloy PJ, Huber BT, Steere AC. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein a of *Borrelia burgdorferi*. *Arthritis and Rheumatism*. 1999; 42(9):1813-1822
31. Choo-Kang C, Tang E, Mattappallil A. The treatment of early lyme disease. *US Pharmacist*. 2010; 35(9):41-48

32. Christian CL. Management of asymptomatic *Borrelia burgdorferi* infection. *Arthritis and Rheumatism*. 1992; 35(11):1395
33. Cimmino MA. Recognition and management of bacterial arthritis. *Drugs*. 1997; 54(1):50-60
34. Cimmino MA, Accardo S. Long term treatment of chronic Lyme arthritis with benzathine penicillin. *Annals of the Rheumatic Diseases*. 1992; 51(8):1007-1008
35. Cimperman J, Maraspin V, Lotric-Furlan S, Ruzic-Sabljić E, Strle F. Lyme meningitis: a one-year follow up controlled study. *Wiener Klinische Wochenschrift*. 1999; 111(22-23):961-963
36. Coblyn JS, Taylor P. Treatment of chronic Lyme arthritis with hydroxychloroquine. *Arthritis and Rheumatism*. 1981; 24(12):1567-1569
37. Commercial Medicines Unit (CMU), Department of Health. Electronic market information tool (EMIT). 2011. Available from: <http://cmu.dh.gov.uk/electronic-market-information-tool-emit/> Last accessed: 4 April 2017.
38. Committee on Infectious Diseases. Erratum: Treatment of Lyme borreliosis (*Pediatrics* (July 1991) 88 (7-19)). *Pediatrics*. 1991; 88(4):840
39. Cuisset T, Hamilos M, Vanderheyden M. Coronary aneurysm in Lyme disease: treatment by covered stent. *International Journal of Cardiology*. 2008; 128(2):e72-e73
40. Curtis L, Burns A. Unit costs of health and social care 2016. Canterbury. Personal Social Services Research Unit University of Kent, 2016. Available from: <http://www.pssru.ac.uk/project-pages/unit-costs/2016/>
41. Dattwyler RJ, Grunwaldt E, Luft BJ. Clarithromycin in treatment of early Lyme disease: a pilot study. *Antimicrobial Agents and Chemotherapy*. 1996; 40(2):468-469
42. Dattwyler RJ, Halperin JJ. Failure of tetracycline therapy in early Lyme disease. *Arthritis and Rheumatism*. 1987; 30(4):448-450
43. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis - randomised comparison of ceftriaxone and penicillin. *Lancet*. 1988; 1(8596):1191-1194
44. Dattwyler RJ, Wormser GP, Rush TJ, Finkel MF, Schoen RT, Grunwaldt E et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. *Wiener Klinische Wochenschrift*. 2005; 117(11-12):393-397
45. Department of Health. NHS reference costs 2015-16. 2016. Available from: <https://www.gov.uk/government/publications/nhs-reference-costs-collection-guidance-for-2015-to-2016> Last accessed: 4 April 2017.
46. Dersch R, Freitag MH, Schmidt S, Sommer H, Rauer S, Meerpohl JJ. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic review. *European Journal of Neurology*. 2015; 22(9):1249-1259
47. Dersch R, Freitag MH, Schmidt S, Sommer H, Rucker G, Rauer S et al. Efficacy and safety of pharmacological treatments for neuroborreliosis--protocol for a systematic review. *Systems Review*. 2014; 3:117
48. Dersch R, Rauer S. Treatment and long-term outcome of Lyme neuroborreliosis. *Aktuelle neurologie*. 2017; 43(10):608-614

49. Dersch R, Sommer H, Rauer S, Meerpohl JJ. Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. *Journal of Neurology*. 2016; 263(1):17-24
50. Dhoot DS, Martin DF, Srivastava SK. Pediatric infectious posterior uveitis. *International Ophthalmology Clinics*. 2011; 51(1):113-128
51. Dinser R, Jendro MC, Schnarr S, Zeidler H. Antibiotic treatment of Lyme borreliosis: what is the evidence? *Annals of the Rheumatic Diseases*. 2005; 64(4):519-523
52. Dotevall L, Alestig K, Hanner P, Norkrans G, Hagberg L. The use of doxycycline in nervous system *Borrelia burgdorferi* infection. *Scandinavian Journal of Infectious Diseases Supplement*. 1988; 53:74-79
53. Dotevall L, Hagberg L. Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis. *Antimicrobial Agents and Chemotherapy*. 1989; 33(7):1078-1080
54. Eliassen KE, Berild D, Reiso H, Grude N, Christophersen KS, Finckenhagen C et al. Incidence and antibiotic treatment of erythema migrans in Norway 2005-2009. *Ticks and Tick-Borne Diseases*. 2017; 8(1):1-8
55. Eliassen KE, Hjetland R, Reiso H, Lindbaek M, Tschudi-Madsen H. Symptom load and general function among patients with erythema migrans: a prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice. *Scandinavian Journal of Primary Health Care*. 2017; 35(1):75-83
56. Eppes SC. Diagnosis, treatment, and prevention of Lyme disease in children. *Pediatric Drugs*. 2003; 5(6):363-372
57. Esposito S, Baggi E, Villani A, Norbedo S, Pellegrini G, Bozzola E et al. Management of paediatric Lyme disease in non-endemic and endemic areas: data from the registry of the Italian Society for Pediatric Infectious Diseases. *European Journal of Clinical Microbiology and Infectious Diseases*. 2013; 32(4):523-529
58. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. *Neurology*. 2008; 70(13):992-1003
59. Fallon BA, Tager F, Fein L, Liegner K, Keilp J, Weiss N et al. Repeated antibiotic treatment in chronic Lyme disease. *Journal of Spirochetal and Tick-borne Diseases*. 1999; 6(4):94-102
60. Galev A, Zvetkov V, Genov K. Pulse therapy with ceftriaxone on Lyme neuroborreliosis. *Problems of Infectious and Parasitic Diseases*. 2005; 33(1):15-17
61. Garkowski A, Zajkowska J, Zajkowska A, Kulakowska A, Zajkowska O, Kubas B et al. Cerebrovascular manifestations of Lyme neuroborreliosis-a systematic review of published cases. *Frontiers in Neurology*. 2017; 8:146
62. Gasser R, Reisinger E, Eber B, Pokan R, Seinost G, Bergloff J et al. Cases of Lyme borreliosis resistant to conventional treatment: improved symptoms with cephalosporin plus specific beta-lactamase inhibition. *Microbial Drug Resistance*. 1995; 1(4):341-344
63. Gasser R, Reisinger E, Sedaj B, Horvarth R, Seinost G, Keplinger A et al. Oral treatment of late Lyme borreliosis with a combination of roxithromycin and co-trimoxazole--a pilot study on 18 patients. *Acta Medica Austriaca*. 1996; 23(3):99-101

64. Gasser R, Wendelin I, Reisinger E, Bergloff J, Feigl B, Schafhalter I et al. Roxithromycin in the treatment of Lyme disease--update and perspectives. *Infection*. 1995; 23 (Suppl.1):S39-43
65. Gerber MA, Shapiro ED, Burke GS, Parcels VJ, Bell GL. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. *New England Journal of Medicine*. 1996; 335(17):1270-1274
66. Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P et al. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. *CMAJ*. 2015; 187(1):E21-E31
67. Goodwin SD, Sproat TT, Russell WL. Management of Lyme disease. *Clinical Pharmacy*. 1990; 9(3):192-205
68. Hansen K, Hovmark A, Lebech AM, Lebech K, Olsson I, Halkier-Sørensen L et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. *Acta Dermato-Venereologica*. 1992; 72(4):297-300
69. Hassler D, Zoller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG. Cefotaxime versus penicillin in the late stage of Lyme disease: prospective, randomized therapeutic study. *Infection*. 1990; 18(1):16-20
70. Horton DB, Taxter AJ, Groh B, Sherry DD, Rose CD. Clinical and treatment factors associated with antibiotic-refractory Lyme arthritis in children. *Arthritis and Rheumatology*. 2017; 68(S10):3140-3143
71. Hu LT, Klempner MS. Update on the prevention, diagnosis, and treatment of Lyme disease. *Advances in Internal Medicine*. 2001; 46:247-275
72. Inboriboon PC. Early recognition and management of Lyme carditis. *International Journal of Emergency Medicine*. 2010; 3(4):489-490
73. Jowett N, Gaudin RA, Banks CA, Hadlock TA. Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes *Laryngoscope*. 2016; Epublication
74. Kaplan RF, Trevino RP, Johnson GM, Levy L, Dornbush R, Hu LT et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? *Neurology*. 2003; 60(12):1916-1922
75. Karkkonen K, Stiernstedt SH, Karlsson M. Follow-up of patients treated with oral doxycycline for Lyme neuroborreliosis. *Scandinavian Journal of Infectious Diseases*. 2001; 33(4):259-262
76. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. *Neurology*. 1994; 44(7):1203-1207
77. Karlsson M, Hammers S, Nilsson-Ehle I, Malmberg AS, Wretling B. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. *Antimicrobial Agents and Chemotherapy*. 1996; 40(5):1104-1107
78. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of *Borrelia burgdorferi*. *Antimicrobial Agents and Chemotherapy*. 1995; 39(5):1127-1133

79. Kilic Muftuoglu I, Aydin Akova Y, Gur Gungor S. A case of Lyme disease accompanied by uveitis and white dot syndrome. *Turkish Journal of Ophthalmology*. 2016; 46(5):241-243
80. Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. *Vector Borne and Zoonotic Diseases*. 2002; 2(4):255-263
81. Klempner MS, Baker PJ, Shapiro ED, Marques A, Dattwyler RJ, Halperin JJ et al. Treatment trials for post-lyme disease symptoms revisited. *American Journal of Medicine*. 2013; 126(8):665-669
82. Kohlhepp W, Oschmann P, Mertens HG. Treatment of Lyme borreliosis. Randomized comparison of doxycycline and penicillin G. *Journal of Neurology*. 1989; 236(8):464-469
83. Korenberg EI, Vorobyeva NN, Moskvitina HG, Gorban Ln. Prevention of borreliosis in persons bitten by infected ticks. *Infection*. 1996; 24(2):187-189
84. Kowalski TJ, Berth WL, Mathiason MA, Agger WA. Oral antibiotic treatment and long-term outcomes of Lyme facial nerve palsy. *Infection*. 2011; 39(3):239-245
85. Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment duration and long-term outcomes of patients with early Lyme disease from a Lyme disease-hyperendemic area. *Clinical Infectious Diseases*. 2010; 50(4):512-520
86. Krbkova L, Stanek G. Therapy of Lyme borreliosis in children. *Infection*. 1996; 24(2):170-173
87. Kuhn M, Grave S, Bransfield R, Harris S. Long term antibiotic therapy may be an effective treatment for children co-morbid with Lyme disease and autism spectrum disorder. *Medical Hypotheses*. 2012; 78(5):606-615
88. Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. *Annals of the Rheumatic Diseases*. 2003; 62(7):655-658
89. Lantos PM, Brinkerhoff RJ, Wormser GP, Clemen R. Empiric antibiotic treatment of erythema migrans-like skin lesions as a function of geography: a clinical and cost effectiveness modeling study. *Vector Borne and Zoonotic Diseases*. 2013; 13(12):877-883
90. Lauhio A, Konttinen YT, Salo T, Tschesche H, Lahdevirta J, Woessner FJ et al. Placebo-controlled study of the effects of three-month lymecyclille treatment on serum matrix metalloproteinases in reactive arthritis. *Annals of the New York Academy of Sciences*. 1994; 732:424-426
91. Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. *Arthritis and Rheumatism*. 1991; 34(1):6-14
92. Liegner KB. Minocycline in Lyme disease. *Journal of the American Academy of Dermatology*. 1992; 26(2 Pt 1):263-264
93. Lipsker D, Antoni-Bach N, Hansmann Y, Jaulhac B. Long-term prognosis of patients treated for erythema migrans in France. *British Journal of Dermatology*. 2002; 146(5):872-876
94. Ljostad U, Eikeland R, Midgard R, Skogvoll E, Skarpass T, Berg A. Oral doxycycline vs. IV centriaxone for European Lyme neuro-borreliosis. A double-blind, randomized controlled clinical trial. *European Journal of Neurology*. 2008; 15(Suppl 3):338-389

95. Ljostad U, Mygland A. Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. *European Journal of Neurology*. 2010; 17(1):118-123
96. Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. *Lancet Neurology*. 2008; 7(8):690-695
97. Loewen PS, Marra CA, Marra F. Systematic review of the treatment of early Lyme disease *Drugs*. 1999; 57(2):157-173
98. Loewen PS, Marra CA, Marra F. Erratum: Systemic review of the treatment of early Lyme disease (*Drugs* (1999) 57 (2) (157-173)). *Drugs*. 2000; 59(3):476
99. Luft BJ, Halperin JJ, Volkman DJ, Dattwyler RJ. Ceftriaxone -an effective treatment of late Lyme borreliosis. *Journal of Chemotherapy*. 1989; 1(Suppl 4):917-919
100. Luft BJ, Volkman DJ, Halperin JJ, Dattwyler RJ. New chemotherapeutic approaches in the treatment of Lyme borreliosis. *Annals of the New York Academy of Sciences*. 1988; 539:352-361
101. Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Treatment of erythema migrans in pregnancy. *Clinical Infectious Diseases*. 1996; 22(5):788-793
102. Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Erythema migrans in pregnancy. *Wiener Klinische Wochenschrift*. 1999; 111(22-23):933-940
103. Maraspin V, Cimperman J, Lotric-Furlan S, Ruzic-Sabljić E, Jurca T, Picken RN et al. Solitary borrelial lymphocytoma in adult patients. *Wiener Klinische Wochenschrift*. 2002; 114(13-14):515-523
104. Maraspin V, Lotric-Furlan S, Cimperman J, Ruzic-Sabljić E, Strle F. Erythema migrans in the immunocompromised host. *Wiener Klinische Wochenschrift*. 1999; 111(22-23):923-932
105. Maraspin V, Lotric-Furlan S, Strle F. Development of erythema migrans in spite of treatment with antibiotics after a tick bite. *Wiener Klinische Wochenschrift*. 2002; 114(13-14):616-619
106. Maraspin V, Ruzic-Sabljić E, Strle F, Cimperman J, Jereb M, Preac-Mursic V. Persistence of *Borrelia burgdorferi* after treatment with antibiotics. *Alpe Adria Microbiology Journal*. 1995; 4(3):211-216
107. Marks CM, Nawn JE, Caplow JA. Antibiotic treatment for chronic Lyme disease -say no to the DRESS. *JAMA Internal Medicine*. 2016; 176(12):1745-1746
108. McGill IG, Bienenstock J. A comparative clinical trial of lymecycline. *British Journal of Clinical Practice*. 1965; 19:462-464
109. Meyerhoff J. Prolonged antibiotic treatment did not relieve chronic symptoms in Lyme disease. *ACP Journal Club*. 2002; 136(2):57
110. Meyerhoff J. Long-term antibiotics after ceftriaxone did not improve quality of life in persistent Lyme disease. *Annals of Internal Medicine*. 2016; 165(2):JC5
111. Millner MM, Thalhammer GH. Neuroborreliosis in childhood: treatment with penicillin sodium and ceftriaxone. *Acta Dermatovenerologica Alpina, Panonica et Adriatica*. 1996; 5(3-4):169-172

112. Millner MM, Thalhammer GH, Dittrich P, Spork KD, Brunner M, Georgopoulos A. Beta-lactam antibiotics in the treatment of neuroborreliosis in children: preliminary results. *Infection*. 1996; 24(2):174-177
113. Morales DS, Siatkowski RM, Howard CW, Warman R. Optic neuritis in children. *Journal of Pediatric Ophthalmology and Strabismus*. 2000; 37(5):254-259
114. Muellegger R, Zoechling N, Schluепен EM, Soyer HP, Hoedl S, Kerl et al. Polymerase chain reaction control of antibiotic treatment in dermatoborreliosis. *Infection*. 1996; 24(1):76-79
115. Muellegger RR, Zoechling N, Soyer HP, Hoedl S, Wienecke R, Volkenandt M et al. No detection of *Borrelia burgdorferi*-specific DNA in erythema migrans lesions after minocycline treatment. *Archives of Dermatology*. 1995; 131(6):678-682
116. Müllegger RR, Millner MM, Stanek G, Spork KD. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children--a prospective study. *Infection*. 1991; 19(4):279-283
117. Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D et al. Prophylaxis with single-dose doxycycline for the prevention of lyme disease after an *Ixodes scapularis* tick bite. *New England Journal of Medicine*. 2001; 345(2):79-84
118. Nadelman RB, Nowakowski J, Forseter G, Bittker S, Cooper D, Goldberg N et al. Failure to isolate *Borrelia burgdorferi* after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. *American Journal of Medicine*. 1993; 94(6):583-588
119. Naglo AS, Wide K. *Borrelia* infection in children. *Acta Paediatrica Scandinavica*. 1989; 78(6):918-922
120. National Collaborating Centre for Women's and Children's Health. Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management. NICE clinical guideline 102. London. RCOG Press, 2010. Available from: <http://guidance.nice.org.uk/CG102>
121. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
122. Neumann R, Aberer E, Stanek G. Treatment and course of erythema chronicum migrans. *Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene - Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology*. 1987; 263(3):372-376
123. NHS Business Services Authority. NHS electronic drug tariff March 2017. Available from: [http://www.drugtariff.nhsbsa.nhs.uk/#/00446515-DC\\_2/DC00446511/Home](http://www.drugtariff.nhsbsa.nhs.uk/#/00446515-DC_2/DC00446511/Home) Last accessed: 4 April 2017.
124. Nimmrich S, Becker I, Horneff G. Intraarticular corticosteroids in refractory childhood Lyme arthritis. *Rheumatology International*. 2014; 34(7):987-994
125. Nowakowski J, McKenna D, Nadelman RB, Cooper D, Bittker S, Holmgren D et al. Failure of treatment with cephalexin for Lyme disease. *Archives of Family Medicine*. 2000; 9(6):563-567
126. Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. *Journal of the American Academy of Dermatology*. 1995; 32(2 Pt 1):223-227

127. Ogrinc K, Logar M, Lotric-Furlan S, Cerar D, Ruzic-Sabljić E, Strle F. Doxycycline versus ceftriaxone for the treatment of patients with chronic Lyme borreliosis. *Wiener Klinische Wochenschrift*. 2006; 118(21):696-701
128. Oksi J, Marjamäki M, Nikoskelainen J, Viljanen MK. *Borrelia burgdorferi* detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. *Annals of Medicine*. 1999; 31(3):225-232
129. Oksi J, Nikoskelainen J, Hiekkänen H, Lauhio A, Peltomaa M, Pitkäranta A et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. *European Journal of Clinical Microbiology and Infectious Diseases*. 2007; 26(8):571-581
130. Oksi J, Nikoskelainen J, Viljanen MK. Comparison of oral cefixime and intravenous ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. *European Journal of Clinical Microbiology and Infectious Diseases*. 1998; 17(10):715-719
131. Peltomaa M, Saxen H, Seppälä I, Viljanen M, Pyykkö I. Paediatric facial paralysis caused by Lyme borreliosis: a prospective and retrospective analysis. *Scandinavian Journal of Infectious Diseases*. 1998; 30(3):269-275
132. Pena CA, Mathews AA, Siddiqi NH, Strickland GT. Antibiotic therapy for Lyme disease in a population-based cohort. *Clinical Infectious Diseases*. 1999; 29(3):694-695
133. Perronne C. Critical review of studies trying to evaluate the treatment of chronic Lyme disease. *Presse Medicale*. 2015; 44(7-8):828-831
134. Pfister HW, Einhäupl KM, Franz P, Garner C. Corticosteroids for radicular pain in Bannwarth's syndrome: a double-blind, randomized, placebo-controlled trial. *Annals of the New York Academy of Sciences*. 1988; 539(1):485-487
135. Pfister HW, Preac-Mursic V, Wilske B, Einhäupl KM. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. *Archives of Neurology*. 1989; 46(11):1190-1194
136. Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhäupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. *Journal of Infectious Diseases*. 1991; 163(2):311-318
137. Pirila V. The penicillin treatment of acrodermatitis atrophicans chronica. *Acta Dermato-Venereologica*. 1951; 31(5):576-591
138. Plorer A, Sepp N, Schmutzhard E, Krabichler S, Trobos S, Schauer G et al. Effects of adequate versus inadequate treatment of cutaneous manifestations of Lyme borreliosis on the incidence of late complications and late serologic status. *Journal of Investigative Dermatology*. 1993; 100(2):103-109
139. Plotkin SA, Peter G. Treatment of Lyme borreliosis. *Pediatrics*. 1991; 88(1):176-179
140. Puchalska B, Niemcunowicz-Janica A, Kondej Muszynska K, Trippner M. Lyme borreliosis--tick borne spirochaetosis among children. *Roczniki Akademii Medycznej w Białymstoku (1995)*. 1996; 41(1):59-61
141. Puri BK, Hakkarainen-Smith JS, Derham A, Monro JA. Co-administration of alpha-lipoic acid and glutathione is associated with no significant changes in serum bilirubin, alkaline phosphatase or gamma-glutamyltranspeptidase levels during the treatment of neuroborreliosis with intravenous ceftriaxone. *Journal of Complementary and Integrative Medicine*. 2015; 12(3):227-230

142. Puri BK, Hakkarainen-Smith JS, Monro JA. The potential use of cholestyramine to reduce the risk of developing *Clostridium difficile*-associated diarrhoea in patients receiving long-term intravenous ceftriaxone. *Medical Hypotheses*. 2015; 84(1):78-80
143. Rebman AW, Crowder LA, Kirkpatrick A, Aucott JN. Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients. *Clinical Rheumatology*. 2015; 34(3):585-589
144. Renaud I, Cachin C, Gerster JC. Good outcomes of Lyme arthritis in 24 patients in an endemic area of Switzerland. *Joint, Bone, Spine: Revue du Rhumatisme*. 2004; 71(1):39-43
145. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J. Ceftriaxone in the treatment of Lyme neuroborreliosis. *Infection*. 1996; 24(1):88-90
146. Rose CD, Fawcett PT, Eppes SC, Klein JD, Gibney K, Doughty RA. Pediatric Lyme arthritis: clinical spectrum and outcome. *Journal of Pediatric Orthopaedics*. 1994; 14(2):238-241
147. Rose CD, Fawcett PT, Gibney KM, Doughty RA. Residual serologic reactivity in children with resolved Lyme arthritis. *Journal of Rheumatology*. 1996; 23(2):367-369
148. Rubin DA, Sorbera C, Nikitin P, McAllister A, Wormser GP, Nadelman RB. Prospective evaluation of heart block complicating early Lyme disease. *PACE - Pacing and Clinical Electrophysiology*. 1992; 15(3):252-255
149. Salazar CA, Rothemich M, Drouin EE, Glickstein L, Steere AC. Human Lyme arthritis and the immunoglobulin G antibody response to the 37-kilodalton arthritis-related protein of *Borrelia burgdorferi*. *Infection and Immunity*. 2005; 73(5):2951-2957
150. Salazar JC, Gerber MA, Goff CW. Long-term outcome of Lyme disease in children given early treatment. *Journal of Pediatrics*. 1993; 122(4):591-593
151. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. *JAMA*. 2016; 315(16):1767-1777
152. Sandstrom M, Bredberg G, Asbrink E, Hovmark A, Holmkvist C. Brainstem response audiometry in chronic Lyme borreliosis. *Scandinavian Audiology*. 1989; 18(4):205-210
153. Schmidt BL, Aberer E, Stockenhuber C, Klade H, Breier F, Luger A. Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in the urine and breast milk of patients with Lyme borreliosis. *Diagnostic Microbiology and Infectious Disease*. 1995; 21(3):121-128
154. Selby G, Bridges SJ, Hanington L. Should Lyme disease affecting the nervous system be treated with oral or intravenous antibiotics? *Archives of Disease in Childhood Education & Practice*. 2008; 93(4):132-134
155. Shadick NA, Phillips CB, Logigian EL, Steere AC, Kaplan RF, Berardi VP et al. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. *Annals of Internal Medicine*. 1994; 121(8):560-567
156. Shadick NA, Phillips CB, Sangha O, Logigian EL, Kaplan RF, Wright EA et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. *Annals of Internal Medicine*. 1999; 131(12):919-926
157. Shemenski J. Cimetidine as a novel adjunctive treatment for early stage Lyme disease. *Medical Hypotheses*. 2016; Epublication

158. Shoemaker RC, Hudnell HK, House DE, Kempen A, Pakes GE. Atovaquone plus cholestyramine in patients coinfecting with *Babesia microti* and *Borrelia burgdorferi* refractory to other treatment. *Advances in Therapy*. 2006; 23(1):1-11
159. Sjöwall J, Fryland L, Nordberg M, Sjogren F, Garpmo U, Jansson C et al. Decreased Th1-type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of erythema migrans. *PLoS One*. 2011; 6(3):e18220
160. Sjöwall J, Ledel A, Ernerudh J, Ekerfelt C, Forsberg P. Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study. *BMC Infectious Diseases*. 2012; 12:186
161. Skogman BH, Croner S, Nordwall M, Eknefelt M, Ernerudh J, Forsberg P. Lyme neuroborreliosis in children: a prospective study of clinical features, prognosis, and outcome. *Pediatric Infectious Disease Journal*. 2008; 27(12):1089-1094
162. Skogman BH, Croner S, Odkvist L. Acute facial palsy in children - a 2-year follow-up study with focus on Lyme neuroborreliosis. *International Journal of Pediatric Otorhinolaryngology*. 2003; 67(6):597-602
163. Skoldenberg B, Stiernstedt G, Karlsson M, Wretling B, Svenungsson B. Treatment of Lyme borreliosis with emphasis on neurological disease. *Annals of the New York Academy of Sciences*. 1988; 539:317-323
164. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. *Annals of Internal Medicine*. 2002; 136(6):421-428
165. Solomon SP, Hilton E, Weinschel BS, Pollack S, Grolnick E. Psychological factors in the prediction of Lyme disease course. *Arthritis Care and Research*. 1998; 11(5):419-426
166. Spathling S, J dK, P H. Therapy of Lyme arthritis with ceftriaxon - histological proof of spirochetes in the synovialis after ineffective therapy. *Zeitschrift für Rheumatologie*. 1992; 51(Suppl 2):40-41
167. Stanek G, Breier F, Menzinger G, Schaar B, Hafner M, Partsch H. Erythema migrans and serodiagnosis by enzyme immunoassay and immunoblot with three borrelia species. *Wiener Klinische Wochenschrift*. 1999; 111(22-23):951-956
168. Steere AC, Green J, Hutchinson GJ, Rahn DW, Pachner AR, Schoen RT et al. Treatment of Lyme disease. *Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene - Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology*. 1987; 263(3):352-356
169. Steere AC, Green J, Schoen RT, Taylor E, Hutchinson GJ, Rahn DW et al. Successful parenteral penicillin therapy of established Lyme arthritis. *New England Journal of Medicine*. 1985; 312(14):869-874
170. Steere AC, Hutchinson GJ, Rahn DW, Sigal LH, Craft JE, DeSanna ET et al. Treatment of the early manifestations of Lyme disease. *Annals of Internal Medicine*. 1983; 99(1):22-26
171. Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhagen NH. Antibiotic therapy in Lyme disease. *Annals of Internal Medicine*. 1980; 93(1 I):1-8
172. Steere AC, Pachner AR, Malawista SE. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. *Annals of Internal Medicine*. 1983; 99(6):767-772

173. Steurer J. Month-long antibiotic therapy has no effect in persistent symptoms of Lyme disease. *Praxis*. 2016; 105(12):723-724
174. Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L. Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease. *International Journal of General Medicine*. 2011; 4:639-646
175. Stricker RB, Green CL, Savely VR, Chamallas SN, Johnson L. Safety of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease. *Minerva Medica*. 2010; 101(1):1-7
176. Strle F, Maraspin V, Lotric-Furlan S, Ruzic-Sabljić E, Cimperman J. Azithromycin and doxycycline for treatment of borrelia culture-positive erythema migrans. *Infection*. 1996; 24(1):64-68
177. Strle F, Maraspin V, Pleterski-Rigler D, Lotric-Furlan S, Ruzic-Sabljić E, Jurca T et al. Treatment of borrelial lymphocytoma. *Infection*. 1996; 24(1):80-84
178. Strle F, Pleterski-Rigler D, Stanek G, Pejovnik-Pustinek A, Ruzic E, Cimperman J. Solitary borrelial lymphocytoma: report of 36 cases. *Infection*. 1992; 20(4):201-206
179. Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. *Infection*. 1993; 21(2):83-88
180. Stupica D, Lusa L, Cerar T, Ruzic-Sabljić E, Strle F. Comparison of post-lyme borreliosis symptoms in erythema migrans patients with positive and negative borrelia burgdorferi sensu lato skin culture. *Vector-Borne and Zoonotic Diseases*. 2011; 11(7):883-889
181. Stupica D, Lusa L, Maraspin V, Bogovic P, Vidmar D, O'Rourke M et al. Correlation of culture positivity, PCR positivity, and burden of *Borrelia burgdorferi sensu lato* in skin samples of erythema migrans patients with clinical findings. *PloS One*. 2015; 10(9):e0136600
182. Suarez-Magdalena O, Fernandez-Jorge B, Campo-Cerecedo F, Varela-Veiga A. Atrophoderma of Pasini and Pierini associated with *Borrelia burgdorferi* treated with doxycycline. *Piel*. 2017; 32(2):120-122
183. Thompson AD, Cohn KA, Shah SS, Lyons T, Welsh EJ, Hines EM et al. Treatment complications in children with Lyme meningitis. *Pediatric Infectious Disease Journal*. 2012; 31(10):1032-1035
184. Thorstrand C, Belfrage E, Bennet R, Malmberg P, Eriksson M. Successful treatment of neuroborreliosis with ten day regimens. *Pediatric Infectious Disease Journal*. 2002; 21(12):1142-1145
185. Thyresson N. The penicillin treatment of acrodermatitis atrophicans chronica (Herxheimer). *Acta Dermato-Venereologica*. 1949; 29(6):572-621
186. Torbahn G, Hofmann H, Allert R, Freitag MH, Dersch R, Fingerle V et al. Efficacy and safety of pharmacological agents in the treatment of erythema migrans in early Lyme borreliosis-systematic review protocol. *Systems Review*. 2016; 5:73
187. Tory HO, Zurakowski D, Sundel RP. Outcomes of children treated for Lyme arthritis: results of a large pediatric cohort. *Journal of Rheumatology*. 2010; 37(5):1049-1055
188. Tseng YJ, Demaria A, Goldmann DA, Mandl KD. Claims-based diagnostic patterns of patients evaluated for lyme disease and given extended antibiotic therapy. *Vector-Borne and Zoonotic Diseases*. 2017; 17(2):116-122

189. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J. Long-term results in patients with Lyme arthritis following treatment with ceftriaxone. *Infection*. 1996; 24(1):98-102
190. Vazquez-Lopez ME, Diez-Morrondo C, Sanchez-Andrade A, Pego-Reigosa R, Diaz P, Castro-Gago M. Articular manifestations in patients with Lyme disease. *Reumatologia Clinica*. 2016; 12(6):327-330
191. Vazquez M, Sparrow SS, Shapiro ED. Long-term neuropsychologic and health outcomes of children with facial nerve palsy attributable to Lyme disease. *Pediatrics*. 2003; 112(2):e93-97
192. Wahlberg P, Granlund H, Nyman D, Panelius J, Seppala I. Treatment of late Lyme borreliosis. *Journal of Infection*. 1994; 29(3):255-261
193. Weber K, Neubert U, Thurmayer R. Antibiotic therapy in early erythema migrans disease and related disorders. *Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene - Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology*. 1987; 263(3):377-388
194. Weber K, Preac-Mursic V, Neubert U, Thurmayer R, Herzer P, Wilske B et al. Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans. *Annals of the New York Academy of Sciences*. 1988; 539:324-345
195. Weissenbacher S, Ring J, Hofmann H. Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study. *Dermatology*. 2005; 211(2):123-127
196. White B, Seaton RA, Evans TJ. Management of suspected lyme borreliosis: experience from an outpatient parenteral antibiotic therapy service. *QJM*. 2013; 106(2):133-138
197. Zochling N, Mullegger RR, Schluepen EM, Soyer HP, Hodl S, Wienecke R et al. Minocycline in early Lyme Borreliosis. *Acta Dermatovenerologica Alpina, Panonica et Adriatica*. 1996; 5(3-4):163-168

## Appendices

### Appendix A: Review protocols

**Table 10: Review protocol for the management of neuroborreliosis**

Question number: 4.3

Relevant section of Scope: management

Field	Content
Review question	What is the most clinically and cost-effective treatment for people with symptoms consistent with neuroborreliosis?
Type of review question	Intervention  A review of health economic evidence related to the same review question was conducted in parallel with this review. For details, see the health economic review protocol for this NICE guideline.
Objective of the review	The review questions on the condition-specific management of Lyme disease aim to identify the most effective treatment in different clinical scenarios. The questions have been developed in a way to identify the evidence for all potential populations and scenarios, even if clinical presentations are more diverse. The population for this review consists of people with symptoms consistent with neuroborreliosis.
Eligibility criteria – population / disease / condition / issue / domain	People with clinical presentations consistent with neuroborreliosis, such as: <ul style="list-style-type: none"> <li>• peripheral nervous system <ul style="list-style-type: none"> <li>○ radiculopathy</li> <li>○ mononeuritis multiplex</li> <li>○ peripheral neuropathy or polyneuropathy</li> <li>○ myopathy (for example, myositis)</li> <li>○ cranial nerve lesions including facial nerve (VII) palsy</li> <li>○ autonomic nerve dysfunction</li> </ul> </li> <li>• central nervous system <ul style="list-style-type: none"> <li>○ white matter lesions</li> <li>○ meningitis</li> <li>○ encephalitis</li> <li>○ seizures</li> <li>○ optic neuritis</li> <li>○ transverse myelitis</li> <li>○ movement disorders (for example, chorea, ataxia)</li> </ul> </li> <li>• psychiatric <ul style="list-style-type: none"> <li>○ psychosis</li> <li>○ depression</li> </ul> </li> <li>• cognitive decline including dementia</li> </ul>
Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)	Antimicrobials, including but not limited to: <ul style="list-style-type: none"> <li>• Penicillins <ul style="list-style-type: none"> <li>○ Amoxicillin (oral, IV)</li> <li>○ Ampicillin (oral, IV)</li> <li>○ Benzylpenicillin sodium / Penicillin G (IV) <ul style="list-style-type: none"> <li>- Including Augmentin (Amoxicillin and clavulanic acid; oral, IV)</li> </ul> </li> </ul> </li> </ul>

Field	Content
	<ul style="list-style-type: none"> <li>○ Phenoxymethylpenicillin / Penicillin V (oral)</li> <li>● Tetracyclines <ul style="list-style-type: none"> <li>○ Doxycycline (oral)</li> <li>○ Minocycline (oral)</li> </ul> </li> <li>● Cephalosporins <ul style="list-style-type: none"> <li>○ Cefotaxime (IV)</li> <li>○ Ceftriaxone (IV)</li> <li>○ Cefuroxime axetil (oral)</li> </ul> </li> <li>● Macrolides <ul style="list-style-type: none"> <li>○ Azithromycin (oral)</li> <li>○ Clarithromycin (oral, IV)</li> </ul> </li> <li>● Fluoroquinolones <ul style="list-style-type: none"> <li>○ Ciprofloxacin (oral, IV)</li> <li>○ Levofloxacin (oral, IV)</li> <li>○ Moxifloxacin (oral, IV)</li> <li>○ Nalidixic acid (oral)</li> <li>○ Norfloxacin (oral)</li> <li>○ Ofloxacin (oral, IV)</li> <li>○ Rifampicin (oral, IV)</li> </ul> </li> </ul> <p>Steroids (corticosteroids)</p>
Eligibility criteria – comparator(s) / control or reference (gold) standard	<ul style="list-style-type: none"> <li>● Any type of intervention compared to each other <ul style="list-style-type: none"> <li>○ If data are available, consider: <ul style="list-style-type: none"> <li>- Type of agent (within class or between class)</li> <li>- Route of administration</li> <li>- Duration of treatment: 1 month versus longer</li> </ul> </li> </ul> </li> <li>● Monotherapy versus polytherapy (any combination)</li> <li>● Antimicrobial treatment or steroids compared to no treatment / placebo</li> </ul>
Outcomes and prioritisation	<p><b>Critical:</b></p> <ol style="list-style-type: none"> <li>1. Quality of life (any validated measure)</li> <li>2. Cure (resolution of neuroborreliosis)</li> <li>3. Reduction of clinical symptoms related to neuroborreliosis</li> <li>4. Relapse of neuroborreliosis symptoms</li> </ol> <p><b>Important:</b></p> <ol style="list-style-type: none"> <li>5. Adverse events</li> </ol>
Eligibility criteria – study design	<ul style="list-style-type: none"> <li>● RCTs</li> <li>● Cohort studies (if no RCT evidence is found)</li> </ul>
Other inclusion exclusion criteria	<p>Date limits for search: none</p> <p>Language: English only</p> <p>Setting: all settings in which NHS care is provided or commissioned</p> <p>The following interventions will not be considered for inclusion:</p> <ul style="list-style-type: none"> <li>● Metronidazole</li> <li>● Trimethoprim</li> </ul>
Proposed sensitivity / subgroup analysis, or meta-regression	<p>The following groups will be considered separately if data are available (strata):</p> <ul style="list-style-type: none"> <li>● Children (under 12 years); young people and adults (12 years and over)</li> <li>● Onset of specific symptoms less than 6 weeks; 6 weeks to 6 months; over 6 months</li> </ul>

Field	Content
	<p>Subgroups (to be investigated if heterogeneity is identified):</p> <ul style="list-style-type: none"> <li>• Pregnant women</li> <li>• People who are immunocompromised</li> <li>• People in whom a previous course of antimicrobial or steroid treatment has failed</li> </ul>
Selection process – duplicate screening / selection / analysis	Studies will be sifted by title and abstract. Potentially significant publications obtained in full text will then be assessed against the inclusion criteria specified in this protocol.
Data management (software)	<p>Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).</p> <p>GRADEpro will be used to assess the quality of evidence for each outcome</p> <p>Bibliographies, citations, study sifting and reference management will be managed using EndNote.</p> <p>Data extractions will be performed using EviBase, a platform designed and maintained by the National Guideline Centre (NGC)</p>
Information sources – databases and dates	<p>Clinical searches Medline, Embase, The Cochrane Library all years</p> <p>Health economic searches Medline, Embase, NHS Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA) all years</p>
Identify if an update	Not applicable
Author contacts	<a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10007">https://www.nice.org.uk/guidance/indevelopment/gid-ng10007</a>
Highlight if amendment to previous protocol	For details, please see section 4.5 of Developing NICE guidelines: the manual.
Search strategy – for one database	For details, please see appendix B
Data collection process – forms / duplicate	A standardised evidence table format will be used, and published as appendix D of the evidence report.
Data items – define all variables to be collected	For details, please see evidence tables in Appendix D (clinical evidence tables) or H (health economic evidence tables).
Methods for assessing bias at outcome / study level	<p>Standard study checklists were used to appraise critically individual studies. For details, please see section 6.2 of Developing NICE guidelines: the manual</p> <p>The risk of bias across all available evidence will be evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/">http://www.gradeworkinggroup.org/</a></p>
Criteria for quantitative synthesis	<p>For details, please see section 6.4 of Developing NICE guidelines: the manual.</p> <p>Meta-analysis will be conducted wherever possible (that is, where similar studies can be combined)</p> <p>In the absence of clinically established MIDs, standard MIDs for dichotomous (25% risk reduction or risk increase) and continuous outcomes (+/-0.5 standard deviation) will be used</p> <p>If heterogeneity is found, the influence of subgroups will be examined</p>
Methods for quantitative analysis – combining studies and exploring	For details, please see the separate Methods report for this guideline.

Field	Content
(in)consistency	
Meta-bias assessment – publication bias, selective reporting bias	For details, please see section 6.2 of Developing NICE guidelines: the manual.
Confidence in cumulative evidence	For details, please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual.
Rationale / context – what is known	For details, please see the introduction to the evidence review.
Describe contributions of authors and guarantor	A multidisciplinary committee developed the evidence review. The committee was convened by the NGC and chaired by Saul Faust in line with section 3 of Developing NICE guidelines: the manual. Staff from the NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details, please see Developing NICE guidelines: the manual.
Sources of funding / support	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Name of sponsor	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Roles of sponsor	NICE funds the NGC to develop guidelines for those working in the NHS, public health and social care in England.
PROSPERO registration number	Not registered

**Table 11: Health economic review protocol**

Review question	All questions – health economic evidence
<b>Objectives</b>	To identify health economic studies relevant to any of the review questions.
<b>Search criteria</b>	<ul style="list-style-type: none"> <li>• Populations, interventions and comparators must be as specified in the clinical review protocol above.</li> <li>• Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</li> <li>• Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</li> <li>• Unpublished reports will not be considered unless submitted as part of a call for evidence.</li> <li>• Studies must be in English.</li> </ul>
<b>Search strategy</b>	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
<b>Review strategy</b>	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2001, abstract-only studies and studies from non-OECD countries or the US will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<sup>121</sup></p> <p><b>Inclusion and exclusion criteria</b></p> <ul style="list-style-type: none"> <li>• If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’, then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</li> </ul>

- If a study is rated as either 'Not applicable' or with 'Very serious limitations', then it will usually be excluded from the guideline. If it is excluded, then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.
- If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both, then there is discretion over whether it should be included.

#### **Where there is discretion**

The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to exclude the remaining studies selectively. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

#### *Setting:*

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the US will be excluded before being assessed for applicability and methodological limitations.

#### *Health economic study type:*

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

#### *Year of analysis:*

- The more recent the study, the more applicable it will be.
- Studies published in 2001 or later but that depend on unit costs and resource data entirely or predominantly before 2001 will be rated as 'Not applicable'.
- Studies published before 2001 will be excluded before being assessed for applicability and methodological limitations.

#### *Quality and relevance of effectiveness data used in the health economic analysis:*

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

## Appendix B: Literature search strategies

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2017  
<https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869>

For more detailed information, please see the Methodology Review.

### B.1 Clinical search literature search strategy

The search for this review was constructed using population terms. An excluded studies filter was applied where appropriate.

**Table 12: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 03 July 2017	Exclusions
Embase (OVID)	1974 – 03 July 2017	Exclusions
The Cochrane Library (Wiley)	Cochrane Reviews to 2017 Issue 7 of 12 CENTRAL to 2017 Issue 6 of 12 DARE, and NHSEED to 2015 Issue 2 of 4 HTA to 2016 Issue 4 of 4	None

#### Medline (Ovid) search terms

1.	exp Borrelia Infections/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodid or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter/
13.	editorial/
14.	news/
15.	exp historical article/
16.	Anecdotes as Topic/
17.	comment/
18.	(letter or comment*).ti.
19.	or/12-18
20.	randomized controlled trial/ or random*.ti,ab.
21.	19 not 20
22.	animals/ not humans/

23.	exp Animals, Laboratory/
24.	exp Animal Experimentation/
25.	exp Models, Animal/
26.	exp Rodentia/
27.	(rat or rats or mouse or mice).ti.
28.	or/21-27
29.	11 not 28
30.	limit 29 to English language

### Embase (Ovid) search terms

1.	exp Borrelia Infection/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissetii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter.pt. or letter/
13.	note.pt.
14.	editorial.pt.
15.	(letter or comment*).ti.
16.	or/12-15
17.	randomized controlled trial/ or random*.ti,ab.
18.	16 not 17
19.	animal/ not human/
20.	Nonhuman/
21.	exp Animal Experiment/
22.	exp Experimental animal/
23.	Animal model/
24.	exp Rodent/
25.	(rat or rats or mouse or mice).ti.
26.	or/18-25
27.	11 not 26
28.	limit 27 to English language

### Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Borrelia Infections] explode all trees
#2.	MeSH descriptor: [Lyme Disease] explode all trees
#3.	MeSH descriptor: [Erythema Chronicum Migrans] explode all trees
#4.	(erythema near/3 migrans):ti,ab
#5.	lyme*:ti,ab
#6.	(tick* near/2 (bite* or bitten or biting or borne)):ti,ab
#7.	acrodermatitis chronica atrophicans:ti,ab

#8.	MeSH descriptor: [Ixodidae] explode all trees
#9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or ixodid or b burgdorferi or b afzelii or b garinii or b bissetii or b valaisiana or b microti):ti,ab
#10.	(granulocytic anaplasmosis or babesia or babesiosis):ti,ab
#11.	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10

## B.2 Health Economics literature search strategy

Health economic evidence was identified by conducting a broad search relating to Lyme disease population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase for health economics, economic modelling and quality of life studies.

**Table 13: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline	1946 – 03 July 2017	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Embase	1974 – 03 July 2017	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 03 July 2017 NHSEED - Inception to March 2015	None

### Medline (Ovid) search terms

1.	exp Borrelia Infections/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodid or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissetii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter/
13.	editorial/
14.	news/
15.	exp historical article/
16.	Anecdotes as Topic/

17.	comment/
18.	(letter or comment*).ti.
19.	or/12-18
20.	randomized controlled trial/ or random*.ti,ab.
21.	19 not 20
22.	animals/ not humans/
23.	exp Animals, Laboratory/
24.	exp Animal Experimentation/
25.	exp Models, Animal/
26.	exp Rodentia/
27.	(rat or rats or mouse or mice).ti.
28.	or/21-27
29.	11 not 28
30.	limit 29 to English language
31.	Economics/
32.	Value of life/
33.	exp "Costs and Cost Analysis"/
34.	exp Economics, Hospital/
35.	exp Economics, Medical/
36.	Economics, Nursing/
37.	Economics, Pharmaceutical/
38.	exp "Fees and Charges"/
39.	exp Budgets/
40.	budget*.ti,ab.
41.	cost*.ti.
42.	(economic* or pharmaco?economic*).ti.
43.	(price* or pricing*).ti,ab.
44.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
45.	(financ* or fee or fees).ti,ab.
46.	(value adj2 (money or monetary)).ti,ab.
47.	or/31-46
48.	exp models, economic/
49.	*Models, Theoretical/
50.	*Models, Organizational/
51.	markov chains/
52.	monte carlo method/
53.	exp Decision Theory/
54.	(markov* or monte carlo).ti,ab.
55.	econom* model*.ti,ab.
56.	(decision* adj2 (tree* or analy* or model*)).ti,ab.
57.	or/48-56
58.	quality-adjusted life years/

59.	sickness impact profile/
60.	(quality adj2 (wellbeing or well being)).ti,ab.
61.	sickness impact profile.ti,ab.
62.	disability adjusted life.ti,ab.
63.	(qal* or qtime* or qwb* or daly*).ti,ab.
64.	(euroqol* or eq5d* or eq 5*).ti,ab.
65.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
66.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
67.	(hui or hui1 or hui2 or hui3).ti,ab.
68.	(health* year* equivalent* or hye or hyes).ti,ab.
69.	discrete choice*.ti,ab.
70.	rosser.ti,ab.
71.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
72.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
73.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
74.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
75.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
76.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
77.	or/58-76
78.	30 and 47
79.	30 and 57
80.	30 and 77

### Embase (Ovid) search terms

1.	exp Borrelia Infection/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter.pt. or letter/
13.	note.pt.
14.	editorial.pt.
15.	Case report/ or Case study/
16.	(letter or comment*).ti.
17.	or/12-16
18.	randomized controlled trial/ or random*.ti,ab.

19.	17 not 18
20.	animal/ not human/
21.	Nonhuman/
22.	exp Animal Experiment/
23.	exp Experimental animal/
24.	Animal model/
25.	exp Rodent/
26.	(rat or rats or mouse or mice).ti.
27.	or/19-26
28.	11 not 27
29.	limit 28 to English language
30.	health economics/
31.	exp economic evaluation/
32.	exp health care cost/
33.	exp fee/
34.	budget/
35.	funding/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/30-42
44.	statistical model/
45.	exp economic aspect/
46.	44 and 45
47.	*theoretical model/
48.	*nonbiological model/
49.	stochastic model/
50.	decision theory/
51.	decision tree/
52.	monte carlo method/
53.	(markov* or monte carlo).ti,ab.
54.	econom* model*.ti,ab.
55.	(decision* adj2 (tree* or analy* or model*)).ti,ab.
56.	or/46-55
57.	quality adjusted life year/
58.	"quality of life index"/
59.	short form 12/ or short form 20/ or short form 36/ or short form 8/
60.	sickness impact profile/
61.	(quality adj2 (wellbeing or well being)).ti,ab.


62.	sickness impact profile.ti,ab.
63.	disability adjusted life.ti,ab.
64.	(qal* or qtime* or qwb* or daly*).ti,ab.
65.	(euroqol* or eq5d* or eq 5*).ti,ab.
66.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
67.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
68.	(hui or hui1 or hui2 or hui3).ti,ab.
69.	(health* year* equivalent* or hye or hyes).ti,ab.
70.	discrete choice*.ti,ab.
71.	rosser.ti,ab.
72.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
73.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
74.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
75.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
76.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
77.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
78.	or/57-77
79.	29 and 43
80.	29 and 56
81.	29 and 78

#### NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Borrelia Infections EXPLODE ALL TREES IN NHSEED,HTA
#2.	MeSH DESCRIPTOR Erythema Chronicum Migrans EXPLODE ALL TREES IN NHSEED,HTA
#3.	((erythema adj3 migrans)) IN NHSEED, HTA
#4.	(lyme*) IN NHSEED, HTA
#5.	((tick* adj2 (bite* or bitten or biting or borne))) IN NHSEED, HTA
#6.	(acrodermatitis chronica atrophicans) IN NHSEED, HTA
#7.	MeSH DESCRIPTOR Ixodidae EXPLODE ALL TREES IN NHSEED,HTA
#8.	((borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti)) IN NHSEED, HTA
#9.	((granulocytic anaplasmosis or babesia or babesiosis)) IN NHSEED, HTA
#10.	MeSH DESCRIPTOR Lyme Disease EXPLODE ALL TREES IN NHSEED,HTA
#11.	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10

## Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the reviews of the management of specific clinical scenarios for Lyme disease



## Appendix D: Clinical evidence tables

Study	Jowett 2016 <sup>73</sup>
Study type	Retrospective cohort study
Number of studies (number of participants)	1 (n=51)
Countries and setting	Conducted in USA; Setting: Specialist hospital
Line of therapy	first line
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Clinical diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	CDC definition for confirmed Lyme disease (facial palsy in addition to EM with known tick exposure, or facial palsy in addition to laboratory evidence of infection consisting of a positive CSF antibody test or positive 2-tier serology testing)
Exclusion criteria	Prior episode of facial palsy, inappropriate documentation of initial treatment, inappropriate antibiotic therapy (that is, onset delayed by 14 days or more following onset of facial palsy, or agent/route/duration of therapy inconsistent with treatment guidelines), recent botulinum toxin administration, absent video documentation of facial function, bilateral involvement
Recruitment or selection of people	People with Lyme disease facial palsy presenting at hospital between January 2002 and August 2015
Age, gender and family origin	Age - Mean (range): 39.6 years (6-72). Gender (M:F): 26:25. Family origin: Not reported
Further population details	1. Immunocompromised people: Not applicable 2. Pregnant women: Not applicable
Indirectness of population	Serious indirectness: Includes children
Interventions	(n=17) Intervention 1: Polytherapy. Antibiotics plus corticosteroids. Duration Not reported. Concurrent medication/care: Not reported Further details: 1. Previous treatment failure: Not applicable  (n=18) Intervention 2: Monotherapy. Antibiotics only. Duration Not reported. Concurrent medication/care: Not reported Further details: 1. Previous treatment failure: Not applicable

Study	Jowett 2016 <sup>73</sup>
Funding	No funding
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONOTHERAPY versus POLY THERAPY	
<p>Protocol outcome 1: Reduction of clinical symptoms</p> <p>- Actual outcome: eFACE composite score at 6 months; MD: 11.40 (95% CI 1.61-21.19), p=0.021</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>- Actual outcome: eFACE composite score at 12 months; MD: 13.70 (95% CI -2.16 to 29.58)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>- Actual outcome: eFACE composite score at 3 months; MD: 9.62 (95% CI 0.19-19.04)</p> <p>Risk of bias: All domain - Very high, Selection - Very high, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Quality of life at Define; Cure (resolution of symptoms); Symptom relapse; Adverse events

Study	Karlsson 1994 <sup>76</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=70)
Countries and setting	Conducted in Sweden; Setting: Dual-centre study
Line of therapy	first line
Duration of study	Follow up (post intervention): 12 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Clinical diagnosis plus exocytosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Clinical signs and symptoms compatible with Lyme neuroborreliosis and pleocytosis
Exclusion criteria	Aged below 12 years, pregnancy, breast feeding, allergy to treatment compounds, antibiotic treatment within preceding 4 weeks
Recruitment or selection of people	Consecutive participants
Age, gender and family origin	Age - Median (range): Penicillin G group: 55 years (16-88); doxycycline group: 49 years (18-74). Gender

<b>Study</b>	<b>Karlsson 1994<sup>76</sup></b>
	(M:F): 19:35. Family origin: Not reported
Further population details	1. Immunocompromised people: Not applicable 2. Pregnant women: Not applicable
Indirectness of population	No indirectness
Interventions	(n=32) Intervention 1: Antibiotics - Benzylpenicillin sodium or Penicillin G. 3 g intravenous every 6 hours. Duration 14 days. Concurrent medication or care: Not reported Further details: 1. Previous treatment failure: Not applicable  (n=38) Intervention 2: Antibiotics - Doxycycline. 200 mg oral every 24 hours. Duration 14 days. Concurrent medication or care: Not reported Further details: 1. Previous treatment failure: Not applicable
Funding	No funding
<b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BENZYLPENICILLIN SODIUM / PENICILLIN G versus DOXYCYCLINE</b>	
<p>Protocol outcome 1: Cure (resolution of symptoms)</p> <p>- Actual outcome: No residual symptoms at 4 weeks; Group 1: 10/23, Group 2: 12/31 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 9; Group 2 Number missing: 7</p> <p>- Actual outcome: No residual symptoms at 3 months; Group 1: 13/22, Group 2: 18/31 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 10; Group 2 Number missing: 7</p> <p>- Actual outcome: No residual symptoms at 6 months; Group 1: 17/21, Group 2: 25/31 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 11; Group 2 Number missing: 7</p> <p>- Actual outcome: No residual symptoms at 12 months; Group 1: 18/21, Group 2: 27/30 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 11; Group 2 Number missing: 8</p>	
<p>Protocol outcome 2: Adverse events</p> <p>- Actual outcome: Adverse events at 14 days; Group 1: 3/32, Group 2: 4/38 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Very high, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Quality of life; Reduction of clinical symptoms; Symptom relapse

Study	Kohlhepp 1989 <sup>82</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=75)
Countries and setting	Conducted in Germany; Setting: Department of neurology
Line of therapy	first line
Duration of study	Follow up (post intervention): 3 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Clinical diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Elevated antibody titre specific to <i>B. burgdorferi</i> in the serum plus at least 3 of the following: radiculitis pain, meningitis symptoms, cranial neuritis, sensory or motor radiculitis, arthritis or carditis, tick bite or EM, specific antibody titre (serum or CSF), lymphocytic pleocytosis, elevated protein (> 50 mg/dl), elevated IgM/IgG/IgA index
Exclusion criteria	Not reported
Recruitment or selection of people	Not reported
Age, gender and family origin	Age - Mean (SD): Penicillin group: men 55.0 years (12.6), women 54.1 years (16.3); doxycycline group: men 49.6 years (14.0), women 55.7 years (14.3). Gender (M:F): 36:39. Family origin: Not reported
Further population details	1. Immunocompromised people: Not applicable 2. Pregnant women: Not applicable
Indirectness of population	No indirectness
Interventions	(n=39) Intervention 1: Antibiotics - Doxycycline. 200 mg on the first 2 days, 100 mg on each of 8 days. Duration 10 days. Concurrent medication/care: Not reported Further details: 1. Previous treatment failure: Not applicable  (n=36) Intervention 2: Antibiotics - Benzylpenicillin sodium / Penicillin G. 20 mega units/day. Duration 10 days. Concurrent medication/care: Not reported Further details: 1. Previous treatment failure: Not applicable
Funding	Funding not stated
<b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DOXYCYCLINE versus BENZYL PENICILLIN SODIUM / PENICILLIN G</b>	
Protocol outcome 1: Reduction of clinical symptoms - Actual outcome: Full or partial remission at 2 weeks; Group 1: 33/39, Group 2: 29/36 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - High, Measurement -	

Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: Serious indirectness, Comments: Unclear how many people had a full remission and how many had a partial remission; Group 1 Number missing: 0; Group 2 Number missing: 0	
Protocol outcomes not reported by the study	Quality of life; Cure (resolution of symptoms); Symptom relapse; Adverse events

Study (subsidiary papers)	Ljostad 2008 <sup>96</sup> (Ljostad 2010 <sup>95</sup> )
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=118)
Countries and setting	Conducted in Norway; Setting: Multi-centre study
Line of therapy	first line
Duration of study	Follow up (post intervention): 1 year
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Clinical diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Neurological symptoms suggestive of Lyme neuroborreliosis plus 1 or more of the following: CSF white-cell count of more than 5 per mL, intrathecal production of Bb antibodies, verified acrodermatitis chronica atrophicans.
Exclusion criteria	Allergy to interventions, previous type 1 reaction to penicillin, treatment with cephalosporin or penicillin or tetracycline in the past 14 days, under 18 years old, pregnancy or breast feeding
Recruitment or selection of people	Consecutive participants
Age, gender and family origin	Age - Mean (SD): Doxycycline group: 54 years (13); ceftriaxone group: 52 years (13). Gender (M:F): Doxycycline group: 28:26; ceftriaxone group: 31:17. Family origin: Not reported
Further population details	1. Immunocompromised people: Not applicable 2. Pregnant women: Not applicable
Extra comments	Mean symptom duration: doxycycline group (10 weeks, SD 19), ceftriaxone group (8 weeks, SD 13)
Indirectness of population	No indirectness
Interventions	(n=59) Intervention 1: Antibiotics - Doxycycline. Oral. 200 mg per day. Duration 14 days. Concurrent medication/care: Not reported Further details: 1. Previous treatment failure: Not applicable  (n=59) Intervention 2: Antibiotics - Ceftriaxone. Intravenous. 2 g per day. Duration 14 days. Concurrent medication/care: Not reported

<b>Study (subsidiary papers)</b>	<b>Ljostad 2008<sup>96</sup> (Ljostad 2010<sup>95</sup>)</b>
	Further details: 1. Previous treatment failure: Not applicable
Funding	Academic or government funding
<b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DOXYCYCLINE versus CEFTRIAXONE</b>	
<p>Protocol outcome 1: Cure (resolution of symptoms)</p> <p>- Actual outcome: Clinical score=0 at 4 months; Group 1: 26/54, Group 2: 16/48</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 5; Group 2 Number missing: 11</p> <p>- Actual outcome: Complete recovery at 1 year; Group 1: 22/44, Group 2: 22/41</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 15; Group 2 Number missing: 18</p> <p>Protocol outcome 2: Reduction of clinical symptoms</p> <p>- Actual outcome: Improvement in clinical score at 4 months; Group 1 Mean; 4.5 (95% CI 3.6-5.5) n=54, Group 2 Mean: 4.4 (95% CI 3.4-5.4) n=48</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 5; Group 2 Number missing: 11</p> <p>- Actual outcome: Improvement in clinical score at 13 days; Group 1 Mean; 3 (95% CI 2-4) n=54, Group 2 Mean; 3.6 (95% CI 2.6-4.7) n=48</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 5; Group 2 Number missing: 11</p> <p>Protocol outcome 3: Adverse events</p> <p>- Actual outcome: Any adverse events at Unclear; Group 1: 21/57, Group 2: 26/56</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2; Group 2 Number missing: 3</p> <p>- Actual outcome: Severe adverse events (cholecystitis, stomatitis, proctitis, allergy) at Unclear; Group 1: 0/57, Group 2: 3/56</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2; Group 2 Number missing: 3</p>	
Protocol outcomes not reported by the study	Quality of life; Symptom relapse

<b>Study</b>	<b>Pfister 1989<sup>135</sup></b>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=21)
Countries and setting	Conducted in Germany; Setting: not reported

Line of therapy	first line
Duration of study	Intervention and follow up: 10 days plus mean 7.7 (2.4 SD)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: clinical diagnosis
Stratum	Adults:
Subgroup analysis within study	Not applicable
Inclusion criteria	clinical signs of acute neuroborreliosis radiculitis (Bannwarth's syndrome) with severe radicular pain and lymphocytic pleocytosis in the CSF, elevated antibody titres against <i>B. burgdorferi</i> or history of arthropod bite or erythema migrans; neuroborreliosis meningitis with history of tick bite or erythema migrans and elevated titres against <i>B. burgdorferi</i>
Exclusion criteria	not reported
Recruitment/selection of people	not reported
Age, gender and family origin	Age - Mean (SD): penicillin group 56.7 (15) years; cefotaxime group 55.4 (10.8) years. Gender (M:F): 12/9. Family origin: not reported
Further population details	1. Immunocompromised people: Not stated or unclear 2. Pregnant women: Not stated / Unclear
Indirectness of population	No indirectness: NA
Interventions	(n=10) Intervention 1: Antibiotics - Benzylpenicillin sodium or Penicillin G. 4 x 5million U/d for intravenously. Duration 10 days. Concurrent medication/care: people were not treated with corticosteroids during antibiotic treatment Further details: 1. Previous treatment failure: Not stated / Unclear  (n=11) Intervention 2: Antibiotics - Cefotaxime. 3 x 2g/d intravenously. Duration 10 days. Concurrent medication/care: people were not treated with corticosteroids during antibiotic treatment Further details: 1. Previous treatment failure: Not stated / Unclear
Funding	Funding not stated
<b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BENZYL PENICILLIN SODIUM / PENICILLIN G versus CEFOTAXIME</b>	
Protocol outcome 1: Cure (resolution of symptoms) - Actual outcome for Adults: normal neurologic findings at mean 7.7 months (2.4 SD); Group 1: 8/10, Group 2: 9/11 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0	
Protocol outcomes not reported by the study	Quality of life; Reduction of clinical symptoms; Symptom relapse; Adverse events

Study	Pfister 1991 <sup>136</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=33)
Countries and setting	Conducted in Germany; Setting: not reported
Line of therapy	first line
Duration of study	Intervention and follow up: 10 days plus mean 8.1 (1.9 SD) months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: clinical diagnosis
Stratum	Adults
Subgroup analysis within study	Not applicable: NA
Inclusion criteria	Lyme neuroborreliosis
Exclusion criteria	seronegative people with painful radiculoneuritis or lymphocytic meningitis who had no history of arthropod bites or erythema migrans within 3 months before disease onset
Recruitment or selection of people	not reported
Age, gender and family origin	Age - Range: 12-84 years. Gender (M:F): 16/14. Family origin: not reported
Further population details	1. Immunocompromised people: Not stated / Unclear 2. Pregnant women: Not stated / Unclear
Indirectness of population	No indirectness: NA
Interventions	(n=16) Intervention 1: Antibiotics - Cefotaxime. 2 g every 8 hours intravenously. Duration 10 days. Concurrent medication/care: not reported Further details: 1. Previous treatment failure: Not stated / Unclear  (n=17) Intervention 2: Antibiotics - Ceftriaxone. 2 g every 24 hours intravenously. Duration 10 days. Concurrent medication/care: not reported Further details: 1. Previous treatment failure: Not stated / Unclear
Funding	Funding not stated
<b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CEFOTAXIME versus CEFTRIAZONE</b>	
Protocol outcome 1: Cure (resolution of symptoms) - Actual outcome for Adults: normal neurologic findings at mean 8.1 (SD 1.9) months; Group 1: 9/15, Group 2: 8/12 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness, Comments: NA; Group 1 Number missing: 1, Reason: 1 excluded due to allergic reaction; Group 2 Number missing: 5, Reason: 3 excluded due to being asymptomatic at beginning of study, other 2 unclear	


Study	Pfister 1991 <sup>136</sup>
<p>Protocol outcome 2: Reduction of clinical symptoms - Actual outcome for Adults: mild residual symptoms at mean 8.1 (SD 1.9) months; Group 1: 5/15, Group 2: 3/12 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: Serious indirectness, Comments: doesn't take in to account baseline symptoms - unclear whether symptoms were reduced; Group 1 Number missing: 1, Reason: 1 excluded due to allergic reaction; Group 2 Number missing: 5, Reason: 3 excluded due to being asymptomatic at beginning of study, other 2 unclear</p> <p>Protocol outcome 3: Adverse events - Actual outcome for Adults: adverse reactions at during treatment; Group 1: 3/16, Group 2: 1/14 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness, Comments: NA; Group 1 Number missing: 0; Group 2 Number missing: 3</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life; Symptom relapse</p>

# Appendix E: Forest plots


## E.1 Doxycycline (PO) versus Benzylpenicillin (IV)

### E.1.1 Neuroborreliosis (unspecified)


**Figure 2: Cure (resolution of symptoms at 4 weeks)**




**Figure 3: Cure (resolution of symptoms at 3 months)**




**Figure 4: Cure (resolution of symptoms at 6 months)**




**Figure 5: Cure (resolution of symptoms at 12 months)**



**Figure 6: Adverse events at 2 weeks**




**Figure 7: Reduction of clinical symptoms (full or partial remission at 2 weeks)**




## E.2 Doxycycline (PO) versus Ceftriaxone (IV)

### E.2.1 Neuroborreliosis (unspecified)


**Figure 8: Cure (resolution of symptoms at 4 months)**




**Figure 9: Cure (resolution of symptoms at 12 months)**




**Figure 10: Reduction of symptoms (improvement in clinical score at 13 days)**




**Figure 11: Reduction of symptoms (improvement in clinical score at 4 months)**



**Figure 12: Adverse events (any adverse events)**




**Figure 13: Adverse events (serious adverse events)**



## E.3 Cefotaxime (IV) versus Benzylpenicillin (IV)

### E.3.1 Acute radiculitis or meningitis after tick-bite


**Figure 14: Cure (resolution of symptoms at mean 7.7 months)**




## E.4 Cefotaxime (IV) versus Ceftriaxone (IV)

### E.4.1 Neuroborreliosis (unspecified)


**Figure 15: Cure (resolution of symptoms at mean 8.1 months)**



**Figure 16: Reduction of symptoms (mild residual symptoms at mean 8.1 months)**




**Figure 17: Adverse events (adverse reactions during treatment)**




## E.5 Antibiotics versus Antibiotics plus Corticosteroids

### E.5.1 Facial palsy


**Figure 18: Reduction of symptoms (eFACE composite score at 3 months)**



**Figure 19: Reduction of symptoms (eFACE composite score at 6 months)**



**Figure 20: Reduction of symptoms (eFACE composite score at 12 months)**



## Appendix F: GRADE tables

**Table 14: Clinical evidence profile: Doxycycline (PO) versus Benzylpenicillin (IV)**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Doxycycline	Benzylpenicillin	Relative (95% CI)	Absolute		
<b>Cure (resolution of symptoms at 4 weeks – follow-up 4 weeks; assessed with: no residual symptoms)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	12/31 (38.7%)	10/23 (43.5%)	RR 0.89 (0.47 to 1.69)	48 fewer per 1000 (from 230 fewer to 300 more)	⊕○○○ VERY LOW	CRITICAL
<b>Cure (resolution of symptoms at 3 months – follow-up 3 months; assessed with: no residual symptoms)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	18/31 (58.1%)	13/22 (59.1%)	RR 0.98 (0.62 to 1.55)	12 fewer per 1000 (from 225 fewer to 325 more)	⊕○○○ VERY LOW	CRITICAL
<b>Cure (resolution of symptoms at 6 months – follow-up 6 months; assessed with: no residual symptoms)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	25/31 (80.6%)	17/21 (81%)	RR 1 (0.76 to 1.3)	0 fewer per 1000 (from 194 fewer to 243 more)	⊕○○○ VERY LOW	CRITICAL
<b>Cure (resolution of symptoms at 12 months – follow-up 12 months; assessed with: no residual symptoms)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	27/30 (90%)	18/21 (85.7%)	RR 1.05 (0.85 to 1.3)	43 more per 1000 (from 129 fewer to 257 more)	⊕○○○ VERY LOW	CRITICAL
<b>Adverse events at 2 weeks (follow-up 2 weeks; assessed with: adverse events)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	4/38 (10.5%)	3/32 (9.4%)	RR 1.12 (0.27 to 4.65)	11 more per 1000 (from 68 fewer to 342 more)	⊕○○○ VERY LOW	IMPORTANT

Reduction of clinical symptoms (full/partial remission at 2 weeks – follow-up 2 weeks; assessed with: full or partial remission)												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>2</sup>	none	33/39 (84.6%)	29/36 (80.6%)	RR 1.05 (0.85 to 1.29)	40 more per 1000 (from 121 fewer to 234 more)	⊕○○○ VERY LOW	CRITICAL

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

<sup>2</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

<sup>3</sup> Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes

**Table 15: Clinical evidence profile: Doxycycline (PO) versus ceftriaxone (IV)**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Doxycycline	Ceftriaxone	Relative (95% CI)	Absolute		
<b>Cure (clinical score=0 at 4 months – follow-up 4 months; assessed with: clinical score=0)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	26/54 (48.1%)	16/48 (33.3%)	RR 1.44 (0.89 to 2.35)	147 more per 1000 (from 37 fewer to 450 more)	⊕⊕○○ LOW	CRITICAL
<b>Cure (complete recovery at 1 year – follow-up 1 years; assessed with: complete recovery)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	22/44 (50%)	22/41 (53.7%)	RR 0.93 (0.62 to 1.4)	38 fewer per 1000 (from 204 fewer to 215 more)	⊕⊕○○ LOW	CRITICAL
<b>Reduction of clinical symptoms at 13 days (measured with: improvement in clinical score; 0-64, lower values are beneficial)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	54	48	Not applicable	MD 0.6 lower (1.98 lower to 0.78 higher)	⊕⊕○○ LOW	CRITICAL
<b>Reduction of clinical symptoms at 4 months (measured with: improvement in clinical score; 0-64, lower values are beneficial)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	54	48	Not applicable	MD 0.1 higher (1.21 lower to 1.41 higher)	⊕⊕⊕○ MODERATE	CRITICAL
<b>Adverse events (assessed with: any adverse events)</b>												

1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	21/57 (36.8%)	26/56 (46.4%)	RR 0.79 (0.51 to 1.23)	97 fewer per 1000 (from 227 fewer to 107 more)	⊕⊕⊕ LOW	IMPORTANT
<b>Adverse events (assessed with: serious adverse events)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	0/57 (0%)	3/56 (5.4%)	OR 0.13 (0.01 to 1.26)	46 fewer per 1000 (from 53 fewer to 13 more)	⊕⊕⊕ VERY LOW	IMPORTANT

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

<sup>2</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

<sup>3</sup> The Peto odds ratio method was used because of a zero event rate in the intervention arm

**Table 16: Clinical evidence profile: Cefotaxime (IV) versus Benzylpenicillin (IV)**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Cefotaxime	Benzylpenicillin	Relative (95% CI)	Absolute		
<b>Cure (normal neurologic findings at mean 7.7 months – follow-up mean 7.7 months; assessed with: normal neurologic findings)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	9/11 (81.8%)	8/10 (80%)	RR 1.02 (0.67 to 1.55)	16 more per 1000 (from 264 fewer to 440 more)	⊕⊕⊕ VERY LOW	CRITICAL

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

<sup>2</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

**Table 17: Clinical evidence profile: Cefotaxime (IV) versus ceftriaxone (IV)**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Cefotaxime	Ceftriaxone	Relative (95% CI)	Absolute		

<b>Cure (normal neurologic findings at mean 8.1 months – follow-up mean 8.1 months; assessed with: normal neurologic findings)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	9/15 (60%)	8/12 (66.7%)	RR 0.9 (0.51 to 1.6)	67 fewer per 1000 (from 327 fewer to 400 more)	⊕○○○ VERY LOW	CRITICAL
<b>Reduction of symptoms (mild residual symptoms at mean 8.1 months – follow-up mean 8.1 months; assessed with: mild residual symptoms)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>2</sup>	none	5/15 (33.3%)	3/12 (25%)	RR 1.33 (0.4 to 4.49)	83 more per 1000 (from 150 fewer to 872 more)	⊕○○○ VERY LOW	CRITICAL
<b>Adverse events during treatment (assessed with: adverse reactions)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	3/16 (18.8%)	1/14 (7.1%)	RR 2.62 (0.31 to 22.46)	116 more per 1000 (from 49 fewer to 1000 more)	⊕○○○ VERY LOW	IMPORTANT

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

<sup>2</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

<sup>3</sup> Downgraded by 1 or 2 increments because the majority of the evidence had indirect outcomes

**Table 18: Clinical evidence profile: Antibiotics versus antibiotics plus corticosteroids**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Antibiotics	Antibiotics plus steroids	Relative (95% CI)	Absolute		
<b>Reduction of symptoms (eFACE composite score at 3 months); 0-100, higher values are beneficial</b>												
1	observational studies	very serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	18	17	Not applicable	MD 9.62 higher (0.19 to 19.05 higher)	⊕○○○ VERY LOW	CRITICAL
<b>Reduction of symptoms (eFACE composite score at 6 months); 0-100, higher values are beneficial</b>												
1	observational studies	very serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	18	17	Not applicable	MD 11.4 higher (1.61 to 21.19 higher)	⊕○○○ VERY LOW	CRITICAL

Reduction of symptoms (eFACE composite score at 12 months); 0-100, higher values are beneficial												
1	observational studies	very serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	18	17	Not applicable	MD 13.7 higher (2.16 lower to 29.56 higher)	⊕○○○ VERY LOW	CRITICAL


<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

<sup>2</sup> Downgraded by 1 or 2 increments because the majority of the evidence included an indirect population (downgrade by 1 increment) or a very indirect population (downgrade by 2 increments)

<sup>3</sup> Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

## Appendix G: Health economic evidence selection

Figure 21: Flow chart of economic study selection for the guideline



\* Non-relevant population, intervention, comparison, design or setting; non-English language

## **Appendix H: Health economic evidence tables**

None.

# Appendix I: Excluded studies

## I.1 Excluded clinical studies

**Table 19: Studies excluded from the clinical management reviews**

Reference	Reason for exclusion
Aberer 2006 <sup>1</sup>	Excluded due to an incorrect intervention
Abrutyn 1989 <sup>2</sup>	Excluded due to an incorrect study design
Agger 1992 <sup>3</sup>	Excluded due to an incorrect study design
Agus 1995 <sup>4</sup>	Excluded due to an incorrect study design
Agwuh 2006 <sup>5</sup>	Excluded due to an incorrect study design
Ahmed 2005 <sup>6</sup>	Excluded due to an incorrect study design
Ahmed 2013 <sup>7</sup>	Excluded due to an incorrect study design
Alarcon 1994 <sup>8</sup>	Excluded due to an incorrect study design
Andiman 1986 <sup>9</sup>	Excluded due to an incorrect study design
Anonymous 1991 <sup>10</sup>	Excluded due to an incorrect study design
Arvikar 2015 <sup>11</sup>	Excluded due to an incorrect study design
Auwaerter 2004 <sup>12</sup>	Excluded due to an incorrect study design
Bennet 2003 <sup>13</sup>	Excluded due to an incorrect study design
Berende 2014 <sup>14</sup>	Excluded due to an incorrect study design
Berger 1988 <sup>16</sup>	Excluded due to an incorrect study design
Berger 1986 <sup>15</sup>	Excluded due to an incorrect study design
Bernardino 2009 <sup>17</sup>	Excluded due to an incorrect study design
Bhate 2011 <sup>18</sup>	Excluded due to an incorrect study design
Bjark 2016 <sup>19</sup>	Not available
Borg 2005 <sup>22</sup>	Excluded due to an incorrect study design
Bratton 2008 <sup>23</sup>	Excluded due to an incorrect study design
Bremell 2014 <sup>24</sup>	Excluded due to an incorrect study design
British Infection Association 2011 <sup>25</sup>	Excluded due to an incorrect study design
Butler 1978 <sup>26</sup>	Excluded due to an incorrect population
Cadavid 2016 <sup>27</sup>	Excluded due to an incorrect study design
Canadian Paediatric Society 1992 <sup>28</sup>	Excluded due to an incorrect study design
Chen 1999 <sup>30</sup>	Excluded due to an incorrect outcome
Choo-Kang 2010 <sup>31</sup>	Excluded due to an incorrect study design
Christian 1992 <sup>32</sup>	Excluded due to an incorrect study design
Cimmino 1992 <sup>34</sup>	Excluded due to an incorrect study design
Cimmino 1997 <sup>33</sup>	Excluded due to an incorrect study design
Cimperman 1999 <sup>35</sup>	Excluded due to an incorrect study design
Coblyn 1981 <sup>36</sup>	Excluded due to an incorrect study design
Committee on Infectious Diseases 1991 <sup>38</sup>	Excluded due to an incorrect study design
Cuisset 2008 <sup>39</sup>	Excluded due to an incorrect study design
Dattwyler 1996 <sup>41</sup>	Excluded due to an incorrect comparison
Dattwyler 1987 <sup>42</sup>	Excluded due to an incorrect study design
Dattwyler 1988 <sup>43</sup>	Excluded due to an incorrect population
Dattwyler 2005 <sup>44</sup>	Excluded due to an incorrect population
Dersch 2015 <sup>46</sup>	Excluded due to an incorrect study design

Reference	Reason for exclusion
Dersch 2016 <sup>49</sup>	Excluded due to an incorrect study design
Dersch 2014 <sup>47</sup>	Excluded due to an incorrect study design
Dersch 2017 <sup>48</sup>	Not available
Dhoot 2011 <sup>50</sup>	Excluded due to an incorrect study design
Dinser 2005 <sup>51</sup>	Excluded due to an incorrect study design
Dotevall 1988 <sup>52</sup>	Excluded due to an incorrect study design
Eliassen 2017 <sup>54</sup>	Excluded due to an incorrect study design
Eliassen 2017 <sup>55</sup>	Excluded due to an incorrect intervention
Eppes 2003 <sup>56</sup>	Excluded due to an incorrect study design
Esposito 2013 <sup>57</sup>	Excluded due to an incorrect study design
Fallon 1999 <sup>59</sup>	Excluded due to an incorrect intervention
Galev 2005 <sup>60</sup>	Excluded due to an incorrect study design
Garkowski 2017 <sup>61</sup>	Systematic review
Gasser 1996 <sup>63</sup>	Not available
Gasser 1995 <sup>64</sup>	Excluded due to an incorrect study design
Gasser 1995 <sup>62</sup>	Excluded due to an incorrect study design
Gerber 1996 <sup>65</sup>	Excluded due to an incorrect intervention
Gillies 2015 <sup>66</sup>	Excluded due to an incorrect study design
Goodwin 1990 <sup>67</sup>	Excluded due to an incorrect study design
Hansen 1992 <sup>68</sup>	Excluded due to an incorrect intervention
Hassler 1990 <sup>69</sup>	Excluded due to an incorrect population
Horton 2017 <sup>70</sup>	Conference abstract
Hu 2001 <sup>71</sup>	Excluded due to an incorrect study design
Inboriboon 2010 <sup>72</sup>	Excluded due to an incorrect study design
Karkkonen 2001 <sup>75</sup>	Excluded due to an incorrect study design
Karlsson 1996 <sup>77</sup>	Excluded due to an incorrect outcome
Kersten 1995 <sup>78</sup>	Excluded due to an incorrect study design
Kilic Muftuoglu 2016 <sup>79</sup>	Excluded due to an incorrect study design
Klempner 2013 <sup>81</sup>	Excluded due to an incorrect study design
Korenberg 1996 <sup>83</sup>	Excluded due to an incorrect intervention
Kowalski 2010 <sup>85</sup>	Excluded due to an incorrect outcome
Kowalski 2011 <sup>84</sup>	Excluded due to an incorrect study design
Krbkova 1996 <sup>86</sup>	Excluded due to an incorrect comparison
Kuhn 2012 <sup>87</sup>	Excluded due to an incorrect study design
Laasila 2003 <sup>88</sup>	Excluded due to an incorrect population
Lantos 2013 <sup>89</sup>	Excluded due to an incorrect study design
Lauhio 1994 <sup>90</sup>	Excluded due to an incorrect population
Lauhio 1991 <sup>91</sup>	Excluded due to an incorrect population
Lempner 2002 <sup>80</sup>	Excluded due to an incorrect study design
Liegner 1992 <sup>92</sup>	Excluded due to an incorrect study design
Lipsker 2002 <sup>93</sup>	Excluded due to an incorrect study design
Ljostad 2008 <sup>94</sup>	Study abstract
Loewen 1999 <sup>97</sup>	Excluded due to an incorrect study design
Loewen 2000 <sup>98</sup>	Excluded due to an incorrect study design
Luft 1988 <sup>100</sup>	Excluded due to an incorrect outcome

Reference	Reason for exclusion
Luft 1989 <sup>99</sup>	Excluded due to an incorrect population
Maraspin 1995 <sup>106</sup>	Excluded due to an incorrect study design
Maraspin 1996 <sup>101</sup>	Excluded due to an incorrect study design
Maraspin 1999 <sup>102</sup>	Excluded due to an incorrect study design
Maraspin 2002 <sup>103</sup>	Excluded due to an incorrect study design
Maraspin 1999 <sup>104</sup>	Excluded due to an incorrect study design
Maraspin 2002 <sup>105</sup>	Excluded due to an incorrect population
Marks 2016 <sup>107</sup>	Excluded due to an incorrect study design
McGill 1965 <sup>108</sup>	Excluded due to an incorrect population
Meyerhoff 2002 <sup>109</sup>	Excluded due to an incorrect study design
Meyerhoff 2016 <sup>110</sup>	Excluded due to an incorrect study design
Millner 1996 <sup>111</sup>	Excluded due to an incorrect outcome
Millner 1996 <sup>112</sup>	Excluded due to an incorrect outcome
Morales 2000 <sup>113</sup>	Excluded due to an incorrect study design
Muellegger 1995 <sup>115</sup>	Excluded due to an incorrect study design
Muellegger 1996 <sup>114</sup>	Excluded due to an incorrect comparison
Mullegger 1991 <sup>116</sup>	Excluded due to an incorrect outcome
Nadelman 1993 <sup>118</sup>	Excluded due to an incorrect study design
Nadelman 2001 <sup>117</sup>	Excluded due to an incorrect population
Naglo 1989 <sup>119</sup>	Excluded due to an incorrect study design
Neumann 1987 <sup>122</sup>	Excluded due to an incorrect study design
Nimmrich 2014 <sup>124</sup>	Excluded due to an incorrect study design
Nowakowski 2000 <sup>125</sup>	Excluded due to an incorrect study design
Nowakowski 1995 <sup>126</sup>	Excluded due to an incorrect study design
Ogrinc 2006 <sup>127</sup>	Excluded due to an incorrect population
Oksi 1999 <sup>128</sup>	Excluded due to an incorrect study design
Oksi 2007 <sup>129</sup>	Excluded due to an incorrect population
Oksi 1998 <sup>130</sup>	Excluded due to an incorrect population
Peltomaa 1998 <sup>131</sup>	Excluded due to an incorrect comparison
Pena 1999 <sup>132</sup>	Excluded due to an incorrect study design
Perronne 2015 <sup>133</sup>	Not available
Pfister 1988 <sup>134</sup>	Excluded due to an incorrect outcome
Pirila 1951 <sup>137</sup>	Excluded due to an incorrect study design
Plorer 1993 <sup>138</sup>	Excluded due to an incorrect study design
Plotkin 1991 <sup>139</sup>	Excluded due to an incorrect study design
Puchalska 1996 <sup>140</sup>	Excluded due to an incorrect study design
Puri 2015 <sup>141</sup>	Excluded due to an incorrect comparison
Puri 2015 <sup>142</sup>	Excluded due to an incorrect study design
Rebman 2015 <sup>143</sup>	Excluded due to an incorrect study design
Renaud 2004 <sup>144</sup>	Excluded due to an incorrect study design
Rohacova 1996 <sup>145</sup>	Excluded due to an incorrect comparison
Rose 1994 <sup>146</sup>	Excluded due to an incorrect study design
Rose 1996 <sup>147</sup>	Excluded due to an incorrect intervention
Rubin 1992 <sup>148</sup>	Excluded due to an incorrect study design
Salazar 2005 <sup>149</sup>	Excluded due to an incorrect intervention

Reference	Reason for exclusion
Salazar 1993 <sup>150</sup>	Excluded due to an incorrect study design
Sanchez 2016 <sup>151</sup>	Excluded due to an incorrect study design
Sandstrom 1989 <sup>152</sup>	Excluded due to an incorrect study design
Schmidt 1995 <sup>153</sup>	Excluded due to an incorrect study design
Selby 2008 <sup>154</sup>	Excluded due to an incorrect study design
Shadick 1994 <sup>155</sup>	Excluded due to an incorrect study design
Shadick 1999 <sup>156</sup>	Excluded due to an incorrect study design
Shemensi 2016 <sup>157</sup>	Excluded due to an incorrect study design
Shoemaker 2006 <sup>158</sup>	Excluded due to an incorrect intervention
Sjowall 2012 <sup>160</sup>	Excluded due to an incorrect intervention
Sjowall 2011 <sup>159</sup>	Excluded due to an incorrect study design
Skogman 2003 <sup>162</sup>	Excluded due to an incorrect intervention
Skogman 2008 <sup>161</sup>	Excluded due to an incorrect study design
Skoldenberg 1988 <sup>163</sup>	Excluded due to an incorrect study design
Smith 2002 <sup>164</sup>	Excluded due to an incorrect study design
Solomon 1998 <sup>165</sup>	Excluded due to an incorrect intervention
Spathling 1992 <sup>166</sup>	Article not in English
Stanek 1999 <sup>167</sup>	Excluded due to an incorrect study design
Steere 1980 <sup>171</sup>	Excluded due to an incorrect study design
Steere 1983 <sup>172</sup>	Excluded due to an incorrect study design
Steere 1987 <sup>168</sup>	Excluded due to an incorrect study design
Steurer 2016 <sup>173</sup>	Article not in English
Stricker 2011 <sup>174</sup>	Excluded due to an incorrect study design
Stricker 2010 <sup>175</sup>	Excluded due to an incorrect study design
Strle 1996 <sup>176</sup>	Excluded due to an incorrect outcome
Strle 1996 <sup>177</sup>	Excluded due to an incorrect outcome
Strle 1992 <sup>178</sup>	Excluded due to an incorrect study design
Strle 1993 <sup>179</sup>	Excluded due to an incorrect outcome
Stupica 2015 <sup>181</sup>	Excluded due to an incorrect comparison
Stupica 2011 <sup>180</sup>	Excluded due to an incorrect comparison
Suarez-Magdalena 2017 <sup>182</sup>	Not available
Thompson 2012 <sup>183</sup>	Excluded due to an incorrect study design
Thorstrand 2002 <sup>184</sup>	Excluded due to an incorrect study design
Thyresson 1949 <sup>185</sup>	Excluded due to an incorrect study design
Torbahn 2016 <sup>186</sup>	Excluded due to an incorrect study design
Tory 2010 <sup>187</sup>	Excluded due to an incorrect comparison
Tseng 2017 <sup>188</sup>	Excluded due to an incorrect outcome
Valesova 1996 <sup>189</sup>	Excluded due to an incorrect comparison
Vazquez 2003 <sup>191</sup>	Excluded due to an incorrect study design
Vazquez-Lopez 2016 <sup>190</sup>	Excluded due to an incorrect study design
Wahlberg 1994 <sup>192</sup>	Excluded due to an incorrect intervention
Weber 1988 <sup>194</sup>	Excluded due to an incorrect study design
Weber 1987 <sup>193</sup>	Excluded due to an incorrect population
Weissenbacher 2005 <sup>195</sup>	Excluded due to an incorrect intervention
White 2013 <sup>196</sup>	Excluded due to an incorrect study design

Reference	Reason for exclusion
Zochling 1996 <sup>197</sup>	Excluded due to an incorrect study design

## I.2 Excluded health economic studies

**Table 20: Studies excluded from the health economic review**

Reference	Reason for exclusion
Ogrinc 2006 <sup>127</sup>	This study was assessed as not applicable. This cost consequence analysis included non-NHS and personal and social services related costs: sick pay. This cost was included in the total costs and no breakdown was presented, therefore it did not report the health-related costs only.